IMIDAZO-PYRIDINES, -PYRIDAZINES, AND -TRIAZINES AS CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula (I) wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Description: TITLE IMIDAZO-PYRIDI ES, -PYRIDAZINES, /AND -TRIAZINES AS CORTICOTROPIN RELEASING FACTOR ANTAGONISTS FIELD OF THE INVENTION This invention relates to novel imidazo-pyridines , - pyridazines, and -triazines, pharmaceutical compositions containing the same and methods of using same in the treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing corticotropin releasing factor (CRF) , including but not limited to disorders induced or facilitated by CRF. BACKGROUND OF THE INVENTION Corticotropin releasing factor, a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) -derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat . Acad. Sci . (USA) 80:4851 (1983); W. Vale et al . , Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec . Prog. Horm. Res . 39:245 (1983); G.F. Koob, Persp. Behav. Med. 2:39 (1985); E.B. De Souza et al., J. Neurosci . 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, Physiological Reviews 69:1 (1989); J.E. Morley, Li fe Sci . 41:527 (1987)]. Clinical data provides evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E.B. De Souza, Hosp. Practice 23:59 (1988)]. In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C.B. Nemeroff et al., Science 226:1342 (1984); CM. Banki et al., Am. J. Psychiatry 144:873 (1987); R.D. France et al . , Biol . Psychiatry 28:86 (1988); M. Arato et al . , Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C.B. Nemeroff et al., Arch. Gen . Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P.W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, Arch . Gen . Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al . , Neuropsychopharmacology 2:53 (1989)]. There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., Life Sci . 31:363 (1982); C.W. Berridge and A.J. Dunn Regul . Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist α-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn, Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K.T. Britton et al., Psychopharmacology 86:170 (1985); K.T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N.R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Rol5-1788) , which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K.T. Britton et al., Psychopharmacol ogy 94:306 (1988)]. The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (α-helical CRF9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC Press p221 (1990)] . In view of the above, efficacious and specific antagonists of CRF are desired as potentially valuable therapeutic agents for the treatment of psychiatric disorders and neurological diseases. It is thus desirable to discover new CRF antagonists. STTMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel imidazo-pyridines, -pyridazines, and -triazines, which are useful as CRF antagonists or pharmaceutically acceptable salts or prodrugs thereof. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. It is another object of the present invention to provide a method for treating psychiatric disorders and neurological diseases comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors ' discovery that compounds of formula I : (I) or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 2 , R 3 , and R 4 are defined below, are CRF antagonists. DETAILED DESCRIPTION OF THE INVENTION [1] Thus, in a first embodiment, the present invention provides a novel compound of formula I: (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Ci-io alkyl, C 2 - 10 alkenyl, C 2 - 1 alkynyl, C 3 - 8 cycloalkyl, C3- 6 cycloalkyl-Cι- 6 alkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, -SO2-C1-10 alkyl, -Sθ 2 ~R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -C0R 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 _ 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 _s cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13 -, -NC0 2 R 14b -, -NCOR 14b - and -NSO 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group „13a -,~ π 14b ~„_,14b _ j „„ π 14b R , CO2 , COR and SO2R ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -OR 13a , -NR 13a R 16a , C 1 - 4 alkoxy-Cι- 4 alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R l is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 / -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and ~CONR 17a R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cχ- 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S (0) m R 18 / -COR 17 , -OC (0) R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19a , -NR 1 C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a., C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι-6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13a , -OC(0)R 14b , -NR 15 COR 13 , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16 , -NR 15a C02R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13 , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl, - (CH 2 ) 1 - 4 -heteroaryl, or - (CH 2 ) 1 - 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, Cι_ 4 alkyl, C3- 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (Cι_ 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, nitro, Cι_ 4 alkoxy, C 1 - 4 haloalkoxy, Cι_ 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (Cι_ 4 alkyl) 2 amino; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, Cι_ 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl- Cι_ 6 alkyl, aryl, aryKCι- 4 alkyl)-, heteroaryl and heteroaryl (Ci_ 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1-4 alkoxy-Cι- 4 alkyl, C 3 -6 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, aryl, aryl (Cι_ 4 alkyl)-, heteroaryl and heteroaryl (Ci_ 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, C 3 - 6 cycloalkyl-Ci- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, and dimethylamino; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- C- 1 -6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 1 0 cycloalkyl, C3-.6 cycloalkyl-Ci-6 alkyl, Cι_2 alkoxy-Cι- 2 alkyl, C 1 - 4 haloalkyl, R 14 S (0) n -Cι_ alkyl, and R 17b R 19b N-C 2 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted 13 with 0-1 substituents selected from the group R , C0 2 R 14 , COR 14 and S0 2 R 14 ; a l l t t.ernative n ly, i .n an -N τπ R17b π R19b moi .et ,y, rR-,17b and , π R19b t .a -k,en together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 _ι 0 cycloalkyl, C 3 _ 6 cycloalkyi-Cι- 6 alkyl and Cι_ haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, Cι_ haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2,3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , Cθ 2 R 1 a , COR 14a and S0 2 R 14a ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted C 1 - 6 linear or branched alkyl or C 3 - 6 cycloalkyl . [2] In a preferred embodiment, the present invention provides a novel compound of formula la: (la) [3] In another preferred embodiment, the present invention provides a novel compound of formula lb: (lb) [4] In another preferred embodiment, the present invention provides a novel compound of formula lc: :ιo [5] In another preferred embodiment, the present invention provides a novel compound of formula Id: (Id) [5a] In a more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ 6 alkyl, C 2 - 6 alkenyl, C 2 -6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , and C3-8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13a , -NR 13 R 16 , C 1 - 2 alkoxy-Cι_ 2 alkyl, and C 3 _ 8 Q cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R is other than a cyclohexyl- (CH 2 ) 2 ~ group; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17 R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19 , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R , CO 2 R , _,~_14b j r . τ -,14b COR and SO2R ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 7 and R 8 are independently selected from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 _ 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl) 2 -amino; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group C 1 -. 4 alkyl, C 1 - 2 haloalkyl, Cι_ 2 alkoxy-C -2 alkyl, C3_6 cycloalkyl-Cι-2 alkyl, aryl (Cι_2 alkyl)-, and heteroaryl (C 1 -2 alkyl)-; R 13a and R 16 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3- 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl (C1-2 alkyl ) - , and heteroaryl (Cι_ 2 alkyl ) - ; R 14a is selected from the group C 1 - 4 alkyl, Cχ_ 2 haloalkyl, Cι_ 2 alkoxy-Cι-2 alkyl, and C3-6 cycloalkyl-Cι_2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, Cι_ 2 haloalkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C 3 -6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 2 alkyl; R 15 is independently selected at each occurrence from the group H, Cι_ 4 alkyl, C3-7 cycloalkyl, C3- 6 cycloalkyl-Cι-6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, Cι_ 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- Cι_6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cι_6 alkyl, C 3 _ιo cycloalkyl, C 3 _ 6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted 13 with 0-1 substituents selected from the group R , C0R 14 , COR 14 and S0 2 R 14 ; R 17 and R 19a are independently selected at each occurrence from the group H, C1-6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C1-4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C1- 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl , benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2, 3-dihydrobenzothienyl, 2, 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0) m R 18 \ -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 1 a and S0 2 R 14a . [5b] In an even more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S and a bond R 1 is substituted Ci-β alkyl; 1 R is substituted with 0-1 substituents selected from the group -CN, -Cθ 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13 -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , -OR 13a , -NR 13 R 16a , Cι- alkoxy-Cι- 2 alkyl, and C 3 _ 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 -. 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 _ group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH (01 3 ) 2 , and CH 2 CH 2 CH 3 ; R 7 and R 8 are independently selected from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH2CH3, OCF3, Br, Cl, F, CF3 , -CN, SCH3 , SO 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 )2 -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 . [5c] In a still more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is substituted Ci; R is substituted with 0-1 substituents selected from the group -CN, -CO 2 CH 3 , and -CO 2 CH2CH 3 ; 1 R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH2CH3, CH(CH 3 ) 2 , CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ;, -CH≡CH, -CH≡C(CH 3 ), CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R l is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH3; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl' group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH (01 3 ) 2 ; R 7 and R 8 are independently selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO2CH3, -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 . [5d] In a further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is substituted (cyclopropyl) -Ci alkyl or (cyclobutyl) -Ci alkyl; R 1 is substituted with 0-1 -CN; R is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [5e] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl) -Ci alkyl substituted with 1 substituent independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH2CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , -CH=CH(CH 3 ), - CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , Cl, F, and CF 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, and isoxazolyl, each heteroaryl being substituted on 0-2 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , OCH 3 , Cl, F, and CF 3 . [5f] In an even further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is selected from the group R 1 is selected from the group (cyclopropyl) CH-CH 3 , (cyclopropyl ) CH-CH 2 CH 3 , (cyclopropyl ) CH-CH 2 OCH 3 , (cyclopropyl ) CH-CH 2 CH 2 CH 3 , (cyclopropyl ) CH-CH 2 CH 2 OCH 3 , (eyelopropyD 2 CH, phenyl (cyclopropyl )CH, furanyl (cyclopropyl) CH, thienyl (cyclopropyl) CH, isoxazolyl (cyclopropyl) CH, (CH 3 -furanyl) (cyclopropyl )CH, (cyclobutyl) CH-CH 3 , (cyclobutyl ) CH-CH 2 CH 3 , (cyclobutyl ) CH-CH 2 OCH 3 , (cyclobutyl ) CH-CH 2 CH 2 CH 3 , (cyclobutyl) CH-CH 2 CH 2 OCH 3 , (cyclobutyl) 2 CH, phenyl (cyclobutyl ) CH, furanyl (cyclobutyl ) CH, thienyl (cyclobutyl )CH, isoxazolyl (cyclobutyl )CH, and (CH 3 -furanyl) (cyclobutyl )CH; [5g] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3/ cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [5h] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 )2, OCH 2 CH 2 CH 3 , OCF3 , Br, Cl, F, and CF 3 . [5i] In another preferred embodiment, the present invention provides a novel compound of formula Id, wherein the compound is selected from the group: 4- (2, 4-Dichlorophenyl) -2-ethyl-l- (1-ethyl) propyl- imidazo [4, 5-c]pyridine; 4- (2, 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl ) ropyl- imidazo[4,5-c]pyridine; 4- (2, 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl) butyl- imidazo[4, 5-c]pyridine; 4- (2, 4-Dichlorophenyl) -2-ethyl-3- (1-methoxy) butyl- imidazo[4, 5-c]pyridine; 4- (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl) ropyl-imidazo [4, 5-c]pyridine; 4- (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl) butyl-imidazo [4, 5-c]pyridine; 4- (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-c]pyridine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- (1-cyclopropyl) propyl- imidazo [4, 5-c] pyridine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- ( 1-cyclopropyl) butyl- imidazo [4, 5-c] pyridine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-3- ( 1-methoxy) butyl- imidazo [4, 5-c] pyridine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl ) propyl-imidazo [4, 5-c] pyridine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl ) butyl-imidazo [4, 5-c] pyridine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-c] pyridine; - (2, 4-Dichlorophenyl) -2-ethyl-l- (1-ethyl ) propyl- imidazo [4 , 5-d] pyridazine; - (2 , 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl) propyl- imidazo [4, 5-d] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-l- ( 1-cyclopropyl ) butyl- imidazo [4, 5-d] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-3- (1-methoxy) butyl- imidazo[ , 5-d] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropy1) propyl-imidazo [4, 5-d] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl)butyl-imidazo[4, 5-d] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-d] pyridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- ( 1-cyclopropyl ) ropyl- imidazo [4, 5-d] pyridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- (1-cyclopropyl ) butyl- imidazo [4, 5-d] pyridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-3- (1-methoxy) butyl- imidazo [4, 5-d] pyridazine; - (2-Methyl-4-methoxy-5- fluorophenyl) -2-ethyl-l- (1- cyclopropyl ) propyl-imidazo [4, 5-d] pyridazine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl) butyl-imidazo [4, 5-d] pyridazine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-d] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-l- ( 1-ethyl ) propyl- imidazo [4, 5-c] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-l- ( 1-cyclopropyl )propyl- imidazo [4, 5-c] pyridazine; - (2 , 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl) butyl- imidazo[4, 5-c] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-3- (1-methoxy) utyl- imidazo [4, 5-c] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl) ropyl-imidazo [4, 5-c] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl ) butyl-imidazo [4, 5-c] pyridazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-c] pyridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- (1-cyclopropyl) propyl- imidazo [4, 5-c] pyridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-l- ( 1-cyclopropyl ) butyl- imidazo [4, 5-c] yridazine; - (2-Chloro-4-methoxyphenyl) -2-ethyl-3- ( 1-methoxy) butyl- imidazo [4, 5-c] pyridazine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl) propyl-imidazo [4, 5-c] pyridazine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl)butyl-imidazo[4, 5-c] pyridazine; - (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-c] pyridazine; - (2, 4-Dichlorophenyl) -2-ethyl-l- (1-ethyl) propyl- imidazo [4, 5-d] triazine; - (2, 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl) propyl- imidazo [4, 5-d] triazine; - (2 , 4-Dichlorophenyl) -2-ethyl-l- (1-cyclopropyl) butyl- imidazo [4, 5-d] triazine; - (2, 4-Dichlorophenyl) -2-ethyl-3- (1-methoxy) butyl- imidazo [4, 5-d] triazine; - (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl) propyl-imidazo [4, 5-d] triazine; 4- (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-l- (1- cyclopropyl)butyl-imidazo[4, 5-d] triazine; 4- (2-Chloro-4-trifluoromethylphenyl) -2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-d] triazine; 4- (2-Chloro-4-methoxyphenyl) -2-ethyl-l- ( 1-cyclopropyl ) ropyl- imidazo [4, 5-d] triazine; 4- (2-Chloro-4-methoxyphenyl) -2-ethyl-l- (1-cyclopropyl) butyl- imidazo[4, 5-d] triazine; 4- (2-Chloro-4-methoxyphenyl) -2-ethyl-3- (1-methoxy) butyl- imidazo [4, 5-d] triazine; 4- (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl ) propyl-imidazo [4 , 5-d] triazine; 4- (2-Methyl-4-methoxy-5-fluorophenyl) -2-ethyl-l- (1- cyclopropyl) butyl-imidazo [4, 5-d] triazine; and, 4- (2-Methyl-4-methoxy-5-fluorophenyl)-2-ethyl-3- (1- methoxy) butyl-imidazo [4, 5-d] triazine; or a pharmaceutically acceptable salt form thereof. [5j] In another more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is C 3 --8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , -NR 15a COR 13 , -N(COR 13a ) , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group _13a r . 14b _~_14b -, r . π 14b „ •, R , CO 2 , COR and SO2R ; and, R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι_ 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, I, C1-.4 haloalkyl, -0R 13a , Cι_ 2 alkoxy-Cι- 2 alkyl, and -NR 13a R 16a . [5k] In another even more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group cyclopropyl, cyclobutyl, and cyclopentyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , and C4-8 cycloalkyl, wherein one carbon atom in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, --SS((00) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and ,14b -NS0 2 R R ,1 is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -0R 13a , C 1 - 2 alkoxy-Cι- 2 alkyl, and -NR 13a R 16a ; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 -. 4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, Ci_ 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17 R 19 , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι-4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , CO2R , „__14b -, r , r . τ -,14b COR and SO2R ; R 2 is selected from the group C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C1-4 alkoxy; R 9 is independently selected at each occurrence from the group H, C1-.4 alkyl and C3- 8 cycloalkyl; R 7 and R 8 are independently selected from the group H, Br, Cl, F, -CN, C1-4 alkyl, C3- 6 cycloalkyl, Cι_4 alkoxy, NH2, C1-4 alkylamino, and (C1-4 alkyl) 2-amino; R 13 is selected from the group C1-4 alkyl, C1-2 haloalkyl, C1-2 alkoxy-Cι_2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl (C1-2 alkyl)-, and heteroaryl (C1-2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy-Cι-4 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C1-4 alkyl, Cι_ 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι_2 alkyl, aryl (C1-2 alkyl)-, and heteroaryl (C1-2 alkyl)-; R 14a is selected from the group C 1 -. 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι-2 alkyl, and C3-6 cycloalkyl-Cι_2 alkyl; R 14b is selected from the group Cι_ 4 alkyl, C 1 - 2 haloalkyl, C - 2 alkoxy-Cι- 2 alkyl, C3- 6 cycloalkyl, and C3- 6 cycloalkyl- Cι_2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 _ 7 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, Cι_ 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, Cι_2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl ; 17 19 17 19 alternatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , 14 C0 2 R COR 14 and S0 2 R 14 ; R 17a and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 _ 6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C3-6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl , benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2, 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 1 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14a and S0 2 R 14a . [51] In another still more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S and a bond 1 R is substituted with 0-1 substituents selected from the group -CN, -Cθ 2 R 13a , and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13 1 R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 - S alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 3 , -OR 13a , -OH, -OCH 3 , -OCH2CH 3 , -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , and -NR 13a R 16a ; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH3, -N(CH 3 )2# -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2; R l is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3 , Br, Cl, F, CF 3 , -CN, SCH3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH3 , CH2CH3 , CH (CH3 ) 2 , and CH2CH2CH3 ; R 7 and R 8 are independently selected from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2/ -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 . [5m] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 )3CH 3 , -CH=CH 2 , -CH=CH(CH 3 ), - CH≡CH, -CH=C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, and CF 3 ; R l is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH3, OCH(CH 3 )2, OCH2CH2CH3, and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH (01 3 ) 2 ; R 7 and R 8 are independently selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 . [5n] In another even further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: 1 R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, and CF 3 ; and, R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 )2, CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [5o] In a still further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [5p] In another still further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [5q] In another more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is selected from the group Ci-10 alkyl, C2-10 alkenyl, C2-1 0 alkynyl, C 3 - 8 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 5 alkyl and C 1 - 4 alkoxy-Cι- 4 alkyl; R is substituted with a C 3 - 8 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl group is replaced by a group selected from the group -0- , -S(0) n -, -NR a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 14b -; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι_ 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -OR 13 , -NR 13a R 16a , C 1 - 2 alkoxy-Cι_ 2 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0- provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15 C0R 18 , -NR 17a R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyi, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2, 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)π,R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a, C0 2 R 14b , COR 14b and S0 2 R 14b ; and, R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SE, -S(0) n R 14b , -COR 13a , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized. [5r] In another even more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι- 6 alkyl, C 2 - 6 alkenyl, C2-6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with a C 3 - 6 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 6 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13 , -NR 13 R 16a , C 1 - 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0- R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C- 1 -4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , Cθ 2 R 14b , „„ π 14b , „ ^ π 14b COR and SO 2 R ; R 2 is selected from the group C 1 - 4 alkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 7 and R 8 are independently selected from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl) 2 -amino; R 9 is independently selected at each occurrence from the group H, Cι_ 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Cι_ 2 alkoxy-Cι_ alkyl, C 3 -6 cycloalkyl-Cι- 2 alkyl, aryl (Cι_ 2 alkyl)-, and heteroaryl (C1-2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl (C1-2 alkyl)-, and heteroaryl (C 1 - 2 alkyl)-; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Cι_ 2 alkoxy-Cι-2 alkyl, and C3-6 cycloalkyl-Cι-2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-2 alkyl; R 15 is independently selected at each occurrence from the group H, C1-4 alkyl, C3_7 cycloalkyl, C3_ 6 cycloalkyl-Cι- 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cι_ 4 alkyl, Br, Cl, F, Cι_ 4 haloalkyl, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 _6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι_2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 9 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C 1 -4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, Cι_ haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, Cι_ 4 haloalkyl, -CN, -OR 17 , -S(0)π^ 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the -.15 ~„ T ^14 _,„_,14a -, r . ,-,14a group R , CO 2 R , COR and SO 2 R [5s] In another still more preferred embodiment, the present invention provides a novel compound of formula Id, wherein: X is selected from the group 0, S and a bond R 1 is Cι_ 6 alkyl; R is substituted with a C 3 - 6 cycloalkyl, wherein one carbon atom in the C 4 - 6 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C \ -t alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, F, CF 3 , -OR 13a , -NR 13 R 16a , -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH2CH2CK3, cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH , - NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) , and CH2CH 2 CH3 ; R 7 and R 8 are independently selected from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH2CH3; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , SO2CH3, -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0CH 3 . [5t] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl )Cι alkyl; R is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH 2 CH 3 , -(CH 2 )3CH 3 , -CH=CH 2 , -CH=CH(CH 3 ), - CH≡CH, -CH=C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 -cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH3, OCH 2 CH3, OCF3, Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 7 and R 8 are independently selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3 , -N (CH 3 ) 2 , -C (0) NH 2 , -C (0) NHCH 3 , and -C (0) N (CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 • [5u] In another even further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: R 1 is (cyclopropyl) Ci alkyl or (cyclobutyl)Cι alkyl; R 1 is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 )3CH 3 -CH=CH 2 , -CH=CH(CH 3 ), - CH≡CH, -CH=C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [5v] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [5w] In another further preferred embodiment, the present invention provides a novel compound of formula Id, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3/ OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [6] In a second embodiment, the present invention provides a novel method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post- traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 - 10 alkenyl, C 2 -10 alkynyl, C 3 - 8 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, -SO 2 -Cι_ι 0 alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -COR 13 , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13a R 16 , -NR 15a C0 2 R 14b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 _ 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13 -, -NC0 2 R 14b -, -NCOR 14b - and 1 AΗ -NS0 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group π 13a ~,„ n l4b _,_ τ -,14b -, ,_,,_. „14b R , C0 2 R , COR and SO 2 R ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι- 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι_ haloalkyl, -OR 13 , -NR 13a R 16a , Ci_ 4 alkoxy-Cι_ 4 alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2, 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C3- 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17 R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , 14b „„ τ ,1 b -, „„ τ^ l4b C0 2 R COR and SO 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -C0R 13a , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15 CONR 13 R 16a , -NR 15a Cθ 2 R 14b , -NR 13 R 16a , and -CONR 13 R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and Cι_ 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (Cι_ 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl ) 2 amino; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι_ 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1-4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl- C1-6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (Cι_ 4 alkyl)-; R 13a and R 15a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- Cι_ 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 -6 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, aryl, aryl (C 1 -. 4 alkyl)-, heteroaryl and heteroaryl (Ci_ 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 1 a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 -6 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 -. 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group Cι_ 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 -6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C3-7 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C3- 7 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 17 is selected at each occurrence from the group H, C 1 - 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, Cι_ haloalkyl, R 14 S (0) n -Cι_ alkyl, and R 17b R 19b N-C 2 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl ; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and S0R 14 ; R 17a and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 _6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl , naphthyl , indanyl and indenyl , each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C - 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2, 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2, 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -CO 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituleenntts selected from the group R , CO 2 R a , COR Λia. and SO2R [7] In a third embodiment, the present invention provides a novel pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I): (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C2-10 alkenyl, C2-10 alkynyl, C 3 - 8 cycloalkyl, C3-6 cycloalkyl-Ci-e alkyl, C1-4 alkoxy-Cι- 4 alkyl, -SO 2 -Cι-ι 0 alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13 , -C0 2 R 13 , -NR 15 COR 13a , -N(COR 13a ) 2 , -NR 1 a CONR 13 R 16a , -NR 15a C0 2 R 14b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NSO 2 R - 1 and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R 1 is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι_ 6 alkyl, C2- 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 -4 haloalkyl, -OR 13a , -NR 13a R 16a , Cι_ alkoxy-Cι_ alkyl, and C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 _ 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -0C(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19 , -NR 15 C0R 18 , -NR 17a R 19 , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2,3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)π 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(C0R 17 ) 2 , -NR 15 CONR 17 R 19a , -NR 15 C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen 15a atom with 0-1 substituents selected from the group R τ -,14b „ π 14b -, _,.- τ -,14b CO 2 R , COR and SO 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 -- 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13 , SH, -S(0) n R 14b , -COR 13a , -OC(0)R 1 b , -NR 15 COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16 , -NR 15a C0 2 R 1 b , -NR 13a R 15a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein an^ sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 -4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and Cι- 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 -4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 -8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl) 2 amino; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 _ 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, aryl, aryl(Cι- 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C3-6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (Cι_ 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Cι_6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 -. 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 15 is independently selected at each occurrence from the group H, Cι_ 4 alkyl, C 3 -7 cycloalkyl, C3_6 cycloalkyl-Cι- 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 1 0 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C 1 -2 alkoxy-Cι-2 alkyl, C1-4 haloalkyl, R 1 S (0) n -Cι_ alkyl, and R 17 R 19b N-C 2 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C 1 -6 alkyl, C3-10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι- 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted 13 with 0-1 substituents selected from the group R , CO 2 R 14 , COR 14 and S0 2 R 14 ; a -lnt.ernative nly, m ■ an ■N N -mR 1 7 π R19b moi .et ,y, R. l7b and -, „R19b t .a ,ken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and SO2R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 _6 cycloalkyl-Cι- 6 alkyl and C 1 -. 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group Cι_ 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2, 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C-ι- 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)π^ 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 )2, -NR 15 CONR 17 R 19 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituleenntts selected from the group R , CO 2 R a , COR ,14a and SO2R In another preferred embodiment, R 1 is other than a cyclohexyl- (CH 2 )ι, 2 , 3, 4, 5, 6, 1 , 8, 9, or 10- group; In another preferred embodiment, R 1 is other than an aryl-(CH 2 )ι, 2 , 3, 4, 5, 6, 1 , 8, 9, or 10- group, wherein the aryl group is substituted or unsubstituted; In another preferred embodiment, R 1 is other than a heteroaryl- (CH 2 )ι, 2, 3, 4, 5, 6, 1 , 8, 9, or lo ~ group, wherein the heteroaryl group is substituted or unsubstituted; In another preferred embodiment , R 1 is other than a heterocyclyl- (CH 2 )ι, 2, 3, 4, 5, 6, 1 , 8, 9, or 10- group, wherein the heterocyclyl group is substituted or unsubstituted; In another preferred embodiment, when D is imidazole or triazole, R 1 is other than unsubstituted Ci, 2 , 3 , 4 , 5 , 6 , 7, 8, 9, or 10 linear or branched alkyl or C-3, 4, 5, 6, 1 , or 8 cycloalkyl. In another preferred embodiment, R la is not substituted with OR 17 . In fourth embodiment, the present invention provides intermediate compounds useful in preparation of the CRF antagonist compounds and processes for making those intermediates, as described in the following description and claims. In a fifth embodiment, the present invention provides CRF antagonist compounds and labelled derivatives thereof as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor. DEFINITIONS The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14. When any variable (e.g., R^) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 6 , then said group may optionally be substituted with up to two R 6 groups and R 6 at each occurrence is selected independently from the definition of R 6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C V F W where v = 1 to 3 and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counter-ion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and " counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3. O]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10- membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl , benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1 , 5, 2-dithiazinyl, dihydrofuro[2, 3 -b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1,3, 4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, SH-1, 2 , 5-thiadiazinyl, 1,2,3- thiadiazolyl, 1, 2 , -thiadiazolyl, 1, 2, 5-thiadiazolyl, 1,3,4- thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1, 2, 3-triazolyl, 1, 2 , 4-triazolyl, 1, 2 , 5-triazolyl, 1,3, 4-triazolyl, and xanthenyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. "Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent . "Substituted" is intended to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group (s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =0) group, then 2 hydrogens on the atom are replaced. "Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host. The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul. 22:27-55 (1984), occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an effective therapeutic agent. The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety or depression in a host. SYNTHESIS The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Each of the references cited below are hereby incorporated herein by reference. The following abbreviations are used herein: AcOH acetic acid t-BuOK potassium tert-butoxide DEAD diethyl azodicarboxylate DMSO dimethyl sulfoxide EtOAcethyl acetate EtOH ethanol NaHMDS sodium bis (trimethylsilyl) amide PPh triphenylphosphine THF tetrahydrofuran TLC thin layer chromatography ( la) The compounds of this invention of formula (la) may be prepared using the methods shown in Scheme 1. In this procedure the 5-chloro-3 ,4-diaminopyridazine precursor may be cyclized to the desired imidazopyridiazines using orthoesters (for R -X- = H, alkyl, alkoxy, etc.), orthocarbonates , carboxylic acids, carboxylic acid esters, alkyl imidates and other reagents appropriate to the product desired, and reaction conditions known to those skilled in the art of organic synthesis. The synthesis of the starting material where R 8 =H, and the chemistry thereof has been described by Kurashi and Castle (J. Het . Chem . 1964, 1, 42). The imidazolepyridazine may then be N-alkylated using, i for example, base promoted conditions (e.g., NaHMDS/R -LG, where LG = halide, sulfonate, or other appropriate leaving i group) or Mitsunobu reaction conditions (e.g., DEAD/PPh 3 /R - OH) . The compounds of formula (la) are then formed by cross coupling with an appropriate arylboronic acid, arylstannane, or arylzinc reagent under known conditions . In the case where i R is a protecting group such as benzyl, p-methoxybenzyl , or tetrahydropyranyl (J. Het . Chem. 1968, 5, 13), the group may be removed and N-alkylation at this point gives compounds of formula (la) . Scheme 2 / Compounds of formula (la) may also be prepared via the method outlined in Scheme 2. Commercially available 4,5- dibromo-pyridazin-3-one is N and/or 0 benzylated then cross coupled in, for example, a Suzuki reaction (D- B(OH) 2 /Pd(PPh 3 ) 4 /Na 2 Cθ 3 ) followed by deprotection. Chlorination using, for example, POCI 3 gives a chloro- pyridazine which may then be reacted for example, with an amidine. N-alkylation of the resulting bicyclic compound using the methods described above affords the desired compounds of formula (la) . Compounds of formula (la) may also be prepared via the method outlined in Scheme 2b. In this procedure, a 2- chloroacetophenone is condensed with a dialkyl malonate (e.g., TiCl 4 /CCl 4 /pyridine/THF) or nitroacetate. The product from this reaction is treated with hydrazine to give an intermediate which is oxidized using, for example, DDQ or NBS to give the pyridazinone intermediate. Chlorination (or bromination) using POCI 3 (or POBr 3 ) affords a chloro- (or bromo-) pyridazine intermediate. This intermediate, where Y = ester in Scheme 2b, may now be converted to the acid (e.g., LiOH/H 2 θ/MeOH/THF) and then subjected to conditions such as the Curtius reaction or modifications thereof (e.g., DPPA, Et 3 N, t-BuOH; TFA/CH 2 CI 2 ), which transform the acid to an amino group. Substitution of the halide with an appropriate amine using, for example, nucleophilic substitution or cross-coupling reactions, affords an intermediate which can then be converted to the desired imidazopyridiazines (la) by cyclization using orthoesters (for R 2 -X- = H, alkyl, alkoxy, etc.), orthocarbonates, carboxylic acids, carboxylic acid esters, alkyl i idates and other reagents appropriate to the product desired, and reaction conditions known to those skilled in the art of organic synthesis. Scheme 2b ,COAlk A A.CI (la) The intermediate where Y = NO 2 in Scheme 2b may be treated with an appropriate amine using, for example, nucleophilic substitution conditions. Reduction of the nitro group to the amine (e.g., Fe/AcOH or sodium dithionite/water/EtOH) affords an intermediate which can then be converted to the desired imidazopyridiazines (la) by cyclization using orthoesters (for R -X- = H, alkyl, alkoxy, etc.), orthocarbonates, carboxylic acids, carboxylic acid esters, alkyl imidates and other reagents appropriate to the product desired, and reaction conditions known to those skilled in the art of organic synthesis. Scheme 3 The compounds of this invention of formula (Id) may be prepared using the methods shown in Scheme 3. In this procedure, the 3, 4-diamino-5-nitropyridine precursor may be cyclized to the desired imidazopyridines using orthoesters 2 (for R -X- = H, alkyl, alkoxy, etc.), orthocarbonates, carboxylic acids, carboxylic acid esters, alkyl imidates and other reagents appropriate to the product desired, and reaction conditions known to those skilled in the art of organic synthesis. The synthesis of the precursor where R 7 and R 8 =H, and the chemistry thereof has been described by Graboyes and Day (J. Am. Chem. Soc . 1957, 79 , 6421) . Reduction of the nitro group using, for example, stannous chloride, provides the amino compound. Conversion of the amino group to a chloride, bromide or iodide may now be effected via diazotization of the amine followed by displacement with halogen anion. The halide compounds may then be N-alkylated using, for example, base promoted conditions (e.g., NaHMDS/R 1 -LG, where LG = halide, sulfonate, or other appropriate leaving group) or Mitsunobu reaction conditions (e.g., DEAD/PPh 3 /R -OH). Cross coupling with an appropriate arylboronic acid, arylstannane, or arylzinc reagent under known conditions to yield compounds of formula (Id) . In the i case where R is a protecting group, the group may now be removed and N-alkylation at this point gives compounds of formula (Id) . Scheme 4 (lb) Compounds of Formula (lb) may be prepared, using the procedures outlined in Scheme 4. The starting material (where Ra is lower alkyl, X and R2 are defined above) may be treated with a compound of the formula D-M (where M = Li, Na, MgBr, MgCl, ZnCl, CeCl 2 and D is defined above) in the presence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to provide the keto-imidazole. Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane) or aromatic hydrocarbons (preferably benzene or toluene) . The imidazolepyridazine can then be formed by reaction with hydrazine in an inert solvent. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from -80 to 120°C. The hydroxypyridazine may then be treated with a halogenating agent to give halo derivatives which may be isolated or prepared in situ. Halogenating agents include, but are not limited to, SOCI 2 , POCI 3 , PCI 3 , PC1 5 , POBr 3 , PBr 3 or PBr 5 . These intermediates may be treated with a compound of the Formula R 7 H in the presence or absence of a base in an inert solvent. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N,N-di- isopropyl-N-ethyl amine or triethylamine) , aromatic amines (preferably pyridine) or alkyl-lithiums in the presence or absence of salts or complexes of Cu, Ce, Mg, Pd, Ni, Zn, Sn. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N- dialkylformamides (preferably dimethylformamide) , N,N- dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . Preferred reaction temperatures range from -20 to 100°C. The resulting compounds may then be reacted with an alkylating agent of the Formula R 1 X (where R 1 is defined above) and X is halo, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy) in the presence or absence of a base in an inert solvent to provide compounds of Formula (Id) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium ethoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N,N-di- isopropyl-N-ethyl amine or triethylamine) , aromatic amines (preferably pyridine) or alkyl-lithiums in the presence or absence of salts or complexes of Cu, Ce, Mg, Pd, Ni, Zn, Sn. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N- dialkylformamides (preferably dimethylformamide) , N,N- dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . Preferred reaction temperatures range from -20 to 100°C. Alternatively, alkylation to compounds of Formula (lb) by treatment with a azodicarboxylate ester R b θ 2 CN=NCθ 2 R b (where R b is a lower alkyl group) and a compound of the Formula R 1 OH in the presence of a triarylphosphine (where aryl is phenyl or furyl, each optionally substituted by 0 to 3 alkyl groups) in an inert solvent. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide) , N,N- dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . Preferred reaction temperatures range from -20 to 100°C. Scheme 5 Compounds of Formula (lb) may also be prepared, using the procedures outlined in Scheme 5. The starting diester may be treated with a reducing agent in inert solvent to afford an aldehyde. Reducing agents include, but are not limited to, alkali metal or alkaline earth metal borohydrides (preferably lithium or sodium borohydride) , borane, dialkylboranes (such as di-isoamylborane) , alkali metal aluminum hydrides (preferably lithium aluminum hydride) , alkali metal (trialkoxy) aluminum hydrides, or dialkyl aluminum hydrides (such as di-isobutylaluminum hydride) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from -80 to 100°C. Alternatively, the aldehyde may be prepared by a two step sequence: treatment with a reducing agent in an inert solvent, followed by treatment with an oxidizing agent in an inert solvent. Reducing agents and inert solvents are defined above. Oxidizing agents include, but are not limited to, combinations of oxalyl chloride, dimethyl sulfoxide and organic bases, Mn02, KMn04, pyridinium dichromate, pyridinium chlorochromate or combinations of S0 3 and organic bases. Organic bases include, but are not limited to, trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . The aldehyde may then be reacted with hydrazine in an inert solvent to form an imidazole. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from -80 to 120°C. The hydroxy group may then be treated with sulfonylating agents in the presence or absence of a base to give alkanesulfonyloxy, arylsulfonyloxy or haloalkylsulfonyloxy derivatives, which may be isolated or used in situ. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride) , arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N,N-di- isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4- dioxane) , N,N-dialkylformamides (preferably dimethylformamide) , N,N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . The sulfonylated intermediates may then be reacted with compounds of the formula D-B(OH)2 in the presence of salts or complexes of Pd, Ni, or Sn, in the presence or absence of a base in an inert solvent to provide compounds of Formula (lb) . Bases may include, but are not limited to, alkaline earth metal carbonates, alkaline earth metal bicarbonates, alkaline earth metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydroxides, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N,N-di- isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4- dioxane), N,N-dialkylformamides (preferably dimethylformamide) , N,N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . Scheme 6 Compounds of Formula (lb) may also be prepared by the procedures outlined in Scheme 6. The starting imidazoles may treated with halogenating agents in an inert solvent to provide a dihalo-imidazole. Halogenating agents include, but are not limited to, S0C1 2 , P0C1 3 , PC1 3 , PC1 5 , POBr 3 , PBr 3 or PBrs. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide) , N,N- dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . One halogen may be replaced via treatment with a compound of Formula R C M (where R c is lower alkyl and M may be Li, Na, MgBr, MgCl, ZnCl, CeCl 2 ) in an inert solvent, followed by reaction with a compound of Formula R 7 - (C=0) -Y (where R 7 is defined above and Y is halogen, lower alkoxy, lower alkanoyloxy or (R d O) 2 (P=0)0 (where R d is lower alkyl or phenyl) ) . The acyl compounds my be protected by reaction with acetal- or ketal- forming reagents (where R d or R e are each lower alkyl , or taken together they form a lower alkylene chain) . These acetal- or ketal- forming reagents may be combinations of lower alkyl alcohols or diols and acids or trialkylorthoformates and acids. Such acids may be present in catalytic or stoichiometric amounts. Such acids include, but are not limited to, alkanoic acids of 2 to 10 carbons (preferably acetic acid) , arylsulfonic acids (preferably p- toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably glyme or diglyme) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N- dialkylformamides (preferably dimethylformamide) , N, N- dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or halocarbons of 1 to 10 carbons and 1 to 10 halogens (preferably chloroform) . Preferred reaction temperatures range from ambient temperature to 150°C. Moiety D may be attached by treatment with a compound of Formula R C M (where R c is lower alkyl and M may be Li, Na, MgBr, MgCl, ZnCl, CeCl 2 ) n an inert solvent, followed by reaction with a compound of Formula D- (C=0) -Y (where D is defined above and Y is halogen, lower alkoxy, lower alkanoyloxy or (R d O) 2 (P=0) 0 (where R d is lower alkyl or phenyl) ) . Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), or aromatic hydrocarbons (preferably benzene or toluene) . Compounds of Formula (lb) may finally be prepared by (a) hydrolysis with an acid, followed by (b) reaction with hydrazine in an inert solvent. Acids include, but are not limited to, alkanoic acids of 2 to 10 carbons (preferably acetic acid) , arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably glyme or diglyme) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide) , N,N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or halocarbons of 1 to 10 carbons and 1 to 10 halogens (preferably chloroform) . Preferred reaction temperatures for steps (a) or (b) range from ambient temperature to 150°C. If intermediates contain functional groups which are sensitive to the reaction conditions employed, these groups may be protected using methods known to those skilled in the art. These methods include, but are not limited to, those described in Protective Groups in Organic Synthesis (Greene, Wuts; 2nd ed. , 1991, John Wiley & Sons, Inc.). Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. Examples Abbreviations used in the Examples are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, H1 H" for proton, "h" for hour or hours, "M" for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "NMR" for nuclear magnetic resonance spectroscopy, "rt" for room temperature, "tic" for thin layer chromatography, "v/v" for volume to volume ratio. "α", "β", "R" and "S" are stereochemical designations familiar to those skilled in the art. Example l 4- (2, 4-Dichlorophenyl) -2-ethyl-l- ( 1-ethyl) propyl- imidazo [4, 5-d] pyridazine Part A: 4, 5-dibromo-2-ethyl-lH-imidazole : To a solution of 2-ethylimidazole (57.6 g, 0.6 moles) in CHCI3 (700 mL) was cooled to 0- 5 °C and then added bromine (76.8 mL, 1.5 moles) dropwise over 60 mins under nitrogen atmosphere. The mixture was stirred at 5 °C for 60 mins and then at room temperature for 2 days. TLC (1:10 MeOH/CH 2 Cl2) revealed disappearence of starting material (Rf=0.25) and showed a new spot (Rf=0.45). The mixture was cooled back to 0 °C and added dropwise 2N aq. NaOH (750 mL) to dissolve the yellow solid separated from the mixture. The aq. layer was separated and extracted the organic layer with 250 mL of 2N NaOH. The combined aq. extracts was acidified to pH 8.0 using con. HC1. The cream colored solid separated was filtered, washed with water and dried in vacuum at 50 °C to afford 55.0 g of desired product (mp 149-150 °C, 36 %) . -" " H NMR (CDCI 3 ) : 31.27-1.3 (t, 3H, CH 3 ), 2.7-2.8 (q, 2H, CH 2 ) . Mass spectrum (CI-NH3) : m/z 255.0 (MH + ) . Part B: 4, 5-dibromo-2-ethyl- 1- ( 1-ethyl ) propyl-1H- imidazole : A mixture of part A material (8.3 g, 0.033 moles), triphenylphosphine (9.4 g, 0.036 moles) and molecular sieves (10 g) in THF (100 mL) was cooled to 0 to - 5 °C and then added 3-pentanol (3.4 g, 0.039 moles) under nitrogen atmosphere. The mixture was stirred at 0 °C for 30 mins and then added disopropylazodicarboxylate (7.2 g, 0.033 moles) dropwise over 20 mis. The mixture was stirred at 0 °C for 2h followed by room temperature for 2 days and TLC (1:50 MeOH/CH 2 Cl 2 ) revealed a new spot at Rf=0.5. The undissolved material was filtered, washed with dichloromethane and stripped off the solvent in vacuum to afford yellow liquid. The crude was purified by flash column chromatography using chloroform as eluent to afford 4.9 g (46.5 %) of colorless Oil. 1 H NMR (CDCI 3 ) : d 0.79-0.84 (t, 6H, 2*CH 3 ), 1.3-1.35 (t, 3H, CH 3 ), 1.82-2.18 (m, 4H, 2*CH 2 ), 2.65-2.72 (q, 2H, CH 2 ), 3.95 ( , IH, CH) . Mass spectrum (CI-NH 3 ) : m/z 325.0 (MH + ) . Part C: 4-bromo-2-ethyl-l- ( 1-ethyl )propyl-lH- imidazole-5-carboxaldehyde: A solution of part B material (3.7 g, 0.0114 moles) in THF (40.0 mL) was cooled to - 78 °C under nitrogen atmosphere and then added dropwise 1.6 M n-BuLi solution in hexane (7.4 mL, 0.0119 moles) over 30 mins. The mixture was stirred at -78 °C for lh and then added dropwise DMF (2.7 mL, 0.0342 moles) over 15 mins. The mixture was stirred at -78 °C for 60 mins and quenched with saturated NH 4 CI (10 mL) at -78 °C. TLC (1:50 MeOH/CH 2 Cl 2 ) revealed a new spot at Rf=0.55 along with disappearence of starting material spot at Rf=0.5. The reaction mixture was extracted with diethyl ether (3 * 25 mL) , washed with brine and dried (MgSθ 4 ) . The solvent was stripped off in vacuo to afford 3.6 g of yellow oil which was purified by flash column chromatography on silica gel using chloroform as eluent to afford 1.97 g (64 % yield) of colorless oil. ^Η NMR (CDCI3): 3 0.73-0.83 (t, 6H, 2*CH 3 ), 1.35-1.40 (t, 3H, CH 3 ), 1.59-2.17 (m, 4H, 2*CH 2 ) , 2.72-2.80 (q, 2H, CH 2 ) , 3.95 (m, IH, CH) , 9.67 (s, IH, CHO). Mass spectrum (CI-NH3) : m/z 275.1 (M+2H) . Part D: 4-bromo-2-ethyl-l- ( 1-ethyl) propyl- 1H- imidazole-5-carboxaldehyde ethylene acetal: A mixture of part C material (1.75 g, 0.0064 moles) in benzene (150 mL) was treated with ethylene glycol (1.2 mL, 0.025 moles), pyridine (0.0035 moles) and p-toluenesulfonic acid mono hydrate (0.0035 moles). The reaction mixture was heated at reflux in a 20 mL capacity Dean-Stark trap equipped apparatus for 24 h and TLC (1:50 MeOH/CH2Cl2) revealed a new spot at Rf=0.35 (visible under iodine). The reaction mixture was cooled to room temperature, diluted with EtOAc (50 mL) , washed with 10 % sodium bicarbonate, brine and dried (MgS0 4 ) . The solvent was evaporated under reduced pressure to furnish yellow oil. The crude was purified by flash column chromatography on silica gel using 25 % ethyl acetate/chloroform mixture to afford 1.96 g (97 %) white solid (mp 70-71 °C). 1 H NMR (CDCI3): 3 0.78-0.89 (t, 6H, 2*CH 3 ), 1.29-1.36 (t, 3H, CH 3 ), 1.77-1.90 (m, 4H, 2*CH 2 ) , 2.70-2.73 (q, 2H, CH 2 ), 3.98-4.3 ( , 5H, CH and 2*CH 2 ), 5.86 (s, IH, CH) . Mass spectrum (CI-NH 3 ) : m/z 317.1 (M + ) . Anal. calcd for Ci 3 H 22 BrιN 2 θ 2 : C, 49.22; H, 6.67; N, 8.83. Found: C, 49.43; H, 6.61; N, 8.78. Part E: 4- (2, 4-dichlorobenzoyl) -2-ethyl-l- ( 1- ethyl) propyl-IH- imidazole- 5-carboxaldehyde : A solution of part D material (1.08 g, 0.0034 moles) in THF (20.0 mL) was cooled to - 78 °C and then added dropwise 1.6 M n-BuLi in hexane (2.4 mL, 0.004 moles) over 15 mins under nitrogen atmosphere. The mixture was stirred at -78 °C for 2 1/2 h and then added a solution of 2, 4-dichlorobenzoyl chloride (0.84 g, 0.004 moles) in THF (5.0 mL) over 15 mins. The mixture was stirred at -78 °C for 6 h followed by room temperature overnight and TLC (30:70 EtOAc/hexane) showed a new spot at Rf= 0.43. The mixture was quenched with saturated NH 4 CI (10.0 ml), extracted with ethyl acetate (3*30 mL) , washed with brine and dried (MgSθ 4 ) . The solvent was stripped off in vacuo to afford crude product which was purified by flash column chromatography on a silica gel using 15 % EtOAC/hexane to afford 0.61 g (44 % yield) of desired product as yellow oil. Mass spectrum (CI-NH3) : m/z 411.2 (M + ) . The acetal was dissolved in acetone (15.0 mL) and treated with 3.0 M aqeous HC1 (30.0 mL) at room temperature. The reaction mixture was stirred for 24 h at this temperature and TLC (30:70 EtOAc/hexane) showed a new spot at Rf=0.55. It was then quenched with saturated NaCl (50.0 ml), extracted with ethyl acetate (3*50 mL) , washed with brine and dried (MgSθ 4 ) . The solvent was removed in vacuum to afford yellow liquid and purified the crude by flash column chromatography on a silica gel using 15 % EtOAC/hexane to afford 0.28 g (51 % yield) of desired product as yellow solid (mp 85-86 °C) . H NMR (CDCI 3 ) : 3 0.785 (m, 6H, 2*CH 3 ) , 1.28-1.33 (t, 3H, CH 3 ) , 1.90-2.23 (m, 4H, 2*CH 2 ) , 2.74-2.82 (q, 2H, CH 2 ), 3.98-4.05 (m, IH, CH) , 7.34-7.37 (d, IH, aromatic), 7.45-7.46 (d, IH, aromatic), 7.55-7.58 (d, IH, aromatic). Mass spectrum (CI- NH 3 ): m/z 367 (M + ) . Anal, calcd for C 1 8H 2 0CI2N 2 O 2 : C, 58.87; H, 5.50; N, 7.64. Found: C, 58.91; H, 5.60; N, 7.44. Part P: 4- (2, 4-dichlorophenyl) -2-ethyl-l- ( 1- ethyl) propyl- imidazo [4, 5-d] pyridazine : A mixture of part E material (0.110 g, 0.0003 moles) in ethanol (15 mL) was treated with anhydrous hydrazine (0.125 g, 0.0039 moles) and refluxed under nitrogen for 4h. TLC (1:10 MeOH/CH 2 Cl 2 ) showed a new spot at Rf=0.6. The solvent was removed under vacuum and purified the crude by flash column chromatography on a silica gel using 1:100 MeOH/CH 2 Cl 2 to afford 105 mg (97 % yield) of the product as yellow oil and tituration of the oil with diethyl ether (1.0 mL) gave 65 mg of white crystalline solid (mp 136-137 °C) . 1 H NMR (CDCI 3 ) : 3 0.82-0.87 (t, 6H, 2*CH 3 ), 1.41-1.46 (t, 3H, CH 3 ), 2.05-2.21 (m, 4H, 2*CH 2 ), 2.95-3.03 (q, 2H, CH 2 ) , 4.16-4.26 (m, IH, CH) , 7.41-7.44 (d, IH, aromatic), 7.58-7.59 (d, IH, aromatic), 7.64-7.67 (d, IH, aromatic), 9.49 (s, IH, 9 CH) . Mass spectrum (CI-NH 3 ) : m/z 363 (M + ) . Anal, calcd for Cι 8 H 20 Cl 2 N 4 : C, 59.51; H, 5.56; N, 15.42. Found: C, 59.53; H, 5.79; N, 14.70. Example 95 4- (2, 4-Dichlorophenyl) -2-ethyl-l- (1- cyclopropy1) propyl- imidazo [4 , 5-c] pyridazine Part A: 4-Ethoxycarbonyl-5- (2, 4-dichlorophenyl ) -1, 6- dihydropyridazin-3-one : A IM solution of TiCl 4 in CH 2 C1 2 (100 mL) was slowly added via syringe to anhydrous THF (500 mL) cooled to -5°C under N 2 with vigorous stirring. After stirring for 15 min, a solution of 2,2 ' , 4 ' -trichloroacetophenone (llg, 49.2 mmol) in THF was added to the mixture, followed by addition of diethyl malonate (7.4 mL, 48.4 mmol). Pyridine (16.5 mL) was then added dropwise, and the reaction mixture was stirred for 16h at room temperature. The mixture was then partitioned between Et 2 θ and water, and the aqueous layer was washed with Et 2 θ. Organic extracts were combined and dried over MgSθ 4 , filtered and evaporated in vacuo to afford the olefin as a pale yellow oil. To a solution of the olefin in EtOH was added 1.5 equivalents of hydrazine monohydrate and 1.5 equivalents of diisopropylethylamine. The mixture was refluxed for 4h, then evaporated in vacuo. The residue was chromatographed on silica gel (100% Hexane to 20% EtOAc/Hexane gradient) to yield 5.8 g of a pale yellow solid. 1 H NMR (300MHz, CDC1 3 ) : 39.39 (s, IH) , 7.42-7.26 (m, 3H) , 4.23 (quart., 2H) , 3.6 (m, IH) , 3.33-3.11 (m, 2H) , 1,27 (t, 3H) . Part B: 3-Bromo-4-ethoxycarbonyl-5- (2, 4- dichlorophenyl) pyridazine : To a solution of 1.1 g of product from Part A in toluene was added 2 equivalents of POBr3 and the mixture was refluxed for 3h. The reaction mixture was evaporated in vacuo and the residue was chromatographed on silica gel to yield desired product (100% Hexane to 15% EtOAc/Hex gradient) . Mass spectrum (APcI): (M+H) + m/z 374.8 (60%), 376.8 (100%), 378.8 (43%). Part C: 4-Amino-3-bromo-5- (2, 4-dichlorophenyl) pyridazine : To a solution of product from Part B in THF was added a solution of 5 equivalents of LiOH monohydrate in water. A small amount of MeOH was added to make the mixture homogenous. The reaction mixture was stirred at room temperature for 3h. The mixture was then partitioned between Et 2 θ and IN HC1. The organic extract was dried over MgS0 4 , filtered, and evaporated in vacuo to give the acid. To a solution of the acid in t-BuOH was added 1.1 equivalents of both DPPA (diphenyphosphorylazide) and triethyamine. The reaction mixture was refluxed for 16h, then concentrated in vacuo. The residue was partitioned between Et 2 θ and water. The organic extract was dried over MgS0 4 , filtered, and evaporated in vacuo. This residue was dissolved in CH 2 CI 2 and trifluoroacetic acid was added. This solution was stirred at room temperature for 4h, then evaporated in vacuo to afford the crude amine. Part D: 4- (2 , 4-Dichlorophenyl) -2-ethyl-l- ( 1- cyclopropyl) propyl-imidazo [4 , 5-c] pyridazine : To a mixture of the amine in toluene is added 1-cyclopropyl-l-propylamine hydrochloride (1.2 equivalents), sodium t-butoxide (2.5 equivalents), Pd 2 (dba) 3 (0.05 equivalents), and BINAP (0.025 equivalents). The reaction mixture is stirred at 70°C for 16h. The mixture is then cooled and partitioned between Et 2 θ and water. The organic extract is dried over MgS0 4 , filtered, and evaporated in vacuo. To the crude residue is added triethylorthopropionate and 1 drop of cone. HC1 and the mixture is refluxed for 3h then evaporated in vacuo. To this residue is added o-xylene and p- toluenesulfonic acid, and this mixture is refluxed for 3h then evaporated in vacuo. The residue is chromatographed on silica gel (100% hexane to 40% EtOAc/Hexane gradient) to yield the title compound. Example 1121 Synthesis of 2-ethyl-l- ( l-ethyl)propyl-4- (2, 4, 6- trimethylphenyl ) -imidazo [4 , 5-d] pyridazine Part A: 2-Ethyl- 1- ( 1-ethyl ) propyl-4- (2 , 4 , 6- trimethylbenzoyl) -IH- imidazole- 5-carboxaldehyde: A mixture of Part D material of Example 1 (0.82 g, 0.0030 moles) in THF (20.0 mL) was cooled to - 78 °C and then added dropwise 1.6 M n-BuLi in hexane (2.0 mL, 0.0033moles) over 15 mins under nitrogen atmosphere. The mixture was stirred at -78 °C for 3 h and then added a solution of 2,4, 6-trimethylbenzoyl chloride (0.60 g, 0.0033 moles) in THF (5.0 mL) over 15 mins. The mixture was stirred at -78 °C for 6 h followed by room temperature overnight for 16 h and TLC (30:70 EtOAc / hexane) showed both starting material and product had same Rf values. The mixture was quenched with saturated NH 4 CI (10.0 ml), extracted with ethyl acetate (3*30 mL) , washed with brine and dried (MgS0 4 ) . The solvent was stripped off in vacuo to afford crude product (1.0 g) as yellow semi solid. Mass spectrum (APcI-positive) : m/z 385.4 (M+H) . The acetal was dissolved in acetone (15.0 mL) and treated with 3.0 M aqeous HC1 (30.0 mL) at room temperature. The reaction mixture was stirred for 24 h at this temperature and TLC (30:70 EtOAc / hexane) showed a new spot at Rf=0.55 along with unreacted starting material acetal. Therefore continued further for 24 h and found to contain still some unreacted starting material. It was then quenched with saturated NaCl (50.0 ml), extracted with ethyl acetate (3*50 mL) , washed with brine and dried (MgS0 4 ) . The solvent was removed in vacuum to afford yellow liquid and purified the crude by flash column chromatography on a silica gel using dichloromethane as eluent to afford 0.3 g (29 % yield) of desired product as yellow solid (mp 119-120 °C) . X H NMR (CDCI3): ? 0.779 (m, 6H, 2*CH 3 ) , 1.26-1.31 (t, 3H, CH 3 ), 1.90-1.95 (m, 4H, 2*CH 2 ) , 2.16-2.31 (2 S, 9H, aromatic CH 3 ) , 2.74-2.81 (q, 2H, CH 2 ), 3.98-4.05 (m, IH, CH) , 6.87 (s, 2H, aromatic), 10.3 (s, IH, CHO). Mass spectrum (CI-NH 3 ) : m/z 341 (M+H) . Anal. calcd for C 21 H 28 N 2 0 2 : C, 74.08; H, 8.30; N, 8.24. Found: C, 74.33; H, 8.41; N, 8.18. Part B: Title Compound: A mixture of Part A material of Example 1121 (0.2 g, 0.00059 moles) in ethanol (15 mL) was treated with anhydrous hydrazine (0.245 g, 0.0077 moles) and refluxed under nitrogen for lh. TLC (1:50 MeOH / CH 2 C1 2 ) showed a new spot at Rf=0.45. The solvent was removed under vacuum and purified the crude by treatment with ethanol to afford white solid (0.2 g, mp 164-165 °C). λ E NMR (CDC1 3 ): ? 0.77-0.82 (t, 6H, 2*CH 3 ) , 1.24-1.29 (t, 3H, CH 3 ), 1.86-1.92 ( , 4H, 2*CH 2 ) , 2.14 (s, 6H, 2*CH 3 ), 2.29 (s, 3H, CH 3 ), 2.68-2.76 (q, 2H, CH 2 ), 5.52 (bs, 3H, CH&NH 2 ), 6.85 (s, 2H, aromatic), 8.16 (s, 1H,-CH=N). Mass spectrum (CI-NH 3 ) : m/z 355 (M+H) . The reaction stopped at hydrazone stage and failed to cyclize even after 48 h in refluxing ethanol. The hydrazone (0.16 g, 0.45 mmol) was taken in 10 mL of ethylene glycol and refluxed for 2h at 200 °C . Mass spectrum (CI-NH 3 ) : m/z 337 (m+H) revealed desired product and cooled the reaction mixture to room temp. and diluted with 25 ml of water, extracted with ethyl acetate (3*15 mL) , washed with brine and dried (MgS0 4 ) . The crude was purified by flash column chromatography on a silica gel using 1: 50 MeOH / CH 2 C1 2 to afford 71 mg (47 % yield) of the product as yellow crystalline solid (mp 151-152 °C) . λ E NMR (CDC1 3 ) : ? 0.82-0.87 (t, 6H, 2*CH 3 ), 1.35-1.41 (t, 3H, CH 3 ), 2.0 (s, 6H, 2*CH 3 ) , 2.1- 2.17 (q, 4H, CH 2 ) , 2.37 (s, 3H, CH 3 ) , 2.92-3.0 (q, 2H, CH 2 ), 4.16-4.22 (m, IH, CH) , 6.98 (s, 2H, aromatic), 9.46 (s, IH, 9 CH) . Mass spectrum (CI-NH 3 ) : m/z 337 (M+H). Anal, calcd for C 2 ιH 28 N 4 : C, 74.96; H, 8.40; N, 16.65. Found: C, 74.77; H, 8.62; N, 15.42. Example 1122 - ( 2 , 4-dichloro-5- fluorophenyl) -2-ethyl-l- (1- ethyl) propyl-imidazo [4, 5-d] pyridazine Part A: 2-ethyl- 1- ( 1-ethyl ) propyl-4- ( 2 , 4- dichloro- 5- fluorobenzoyl) - IH- imidazole-5- carboxaldehyde : A mixture of Part D material of Example 1 (0.82 g, 0.0030 moles) in THF (20.0 mL) was cooled to - 78 °C and then added dropwise 1.6 M n-BuLi in hexane (2.0 mL, 0.0033moles) over 15 mins under nitrogen atmosphere. The mixture was stirred at -78 °C for 3 h and then added a solution of 2, 4-dichloro-5-F- benzoyl chloride (0.75 g, 0.0033 moles) in THF (5.0 mL) over 15 mins. The mixture was stirred at -78 °C for 6 h followed by room temperature overnight for 16 h and TLC (30:70 EtOAc / hexane) showed absence of starting material (Rf=0.5) and a new spot for the product at Rf=0.64. The mixture was quenched with saturated NH 4 C1 (25.0 ml), extracted with ethyl ether (3*30 mL) , washed with brine and dried (MgS0 4 ) . The solvent was stripped off in vacuo to afford crude product (1.5 g) as yellow oil and purified by flash column chromatography on a silica gel using dichloromethane as eluent to afford desired product as colorless viscous oil (0.62 g, 48 %) . X H NMR (CDC1 3 ): ? 0.86-0.91 (t, 6H, 2*CH 3 ), 1.25-1.30 (t, 3H, CH 3 ), 1.83-1.92 (q, 4H, 2*CH 2 ), 2.70-2.75 (q, 2H, CH 2 ), 2.74-2.81 (q, 2H, CH 2 ) , 4.04-4.18 (m, 4H, 2*OCH 2 ), 4.41-4.51 ( , IH, CH) , 6.69 (s, IH, -CH) , 7.38-7.31 (d, IH, aromatic), 7.45-7.47 (d, IH, aromatic). Mass spectrum (APcI-positive) : m/z 429.2 (M + ) . The acetal was dissolved in acetone (15.0 mL) and treated with 3.0 M aqeous HC1 (30.0 mL) at room temperature. The reaction mixture was stirred for 24 h at this temperature and TLC (30:70 EtOAc / hexane) showed a new spot at Rf=0.67 along with disappearence of starting material acetal. It was then quenched with saturated NaCl (50.0 ml), extracted with ethyl acetate (3*50 mL) , washed with brine and dried (MgS0 4 ) . The solvent was removed in vacuum to afford yellow liquid and purified the crude by flash column chromatography on a silica gel using dichloromethane as eluent to afford 0.43 g (80 % yield) of desired product as white solid (mp 70-71°C) . 1 H NMR (CDC1 3 ) : ? 0.79 (m, 6H, 2*CH 3 ) , 1.28-1.33 (t, 3H, CH 3 ) , 1.90-2.2 (m, 4H, 2*CH 2 ), 2.74-2.82 (q, 2H, CH 2 ) , 3.98- 4.05 (m, IH, CH) , 7.42-7.45 (d, IH, aromatic), 7.50-7.52 (d, IH, aromatic), 10.4 (s, IH, CHO). Mass spectrum (CI- NH 3 ) : m/z 385 (M + ) . Anal, calcd for Cι 8 H 19 N 2 0 2 Cl 2 F 1 : C, 56.12; H, 4.97; N, 7.27. Found: C, 56.27; H,4.95; N,7.12. Part B: Title Compound: A mixture of Part A material of Example 1122 (0.230 g, 0.0006 moles) in ethanol (15 mL) was treated with anhydrous hydrazine (0.25 g, 0.0077 moles) and refluxed under nitrogen for 16 h. TLC (1:10 MeOH / CH 2 C1 2 ) showed a new spot at Rf=0.6. The solvent was removed under vacuum and purified the crude by flash column chromatography on a silica gel using 1:50 MeOH / CH 2 C1 2 to afford 194 mg of pale yellow oil and tituration of the oil with hexane (1.0 mL) gave 59 mg (26 %) of white crystalline solid (mp 85-87 °C) . X H NMR (CDCI 3 ) : ? 0.82-0.87 (t, 6H, 2*CH 3 ), 1.42-1.47 (t, 3H, CH 3 ), 2.08-2.21 (m, 4H, 2*CH 2 ) , 2.98-3.03 (q, 2H, CH 2 ) , 4.16-4.26 (m, IH, CH) , 7.53-7.56 (d, IH, aromatic), 7.62-7.64 (d, IH, aromatic), 9.50 (s, IH, 9 CH) . Mass spectrum (CI-NH 3 ) : m/z 381 (M + ) . HRMS calcd. for C 18 H 20 C1 2 F 1 N 4 : 381.1048. Found: 381.1057 (M+H) . Example 1123 2 -Ethyl -1- ( 1-ethyl ) propyl -4- (2,4- dimethoxybenzoyl ) - IH- imidazole-5-carboxaldehyde A mixture of Part D material of Example 1 (0.82 g, 0.0030 moles) in THF (20.0 mL) was cooled to - 78 °C and then added dropwise 1.6 M n-BuLi in hexane (2.0 mL, 0.0033moles) over 15 mins under nitrogen atmosphere. The mixture was stirred at -78 °C for 3 h and then added a solution of 2,4 -dimethoxybenzoyl chloride (0.66 g, 0.0033 moles) in THF (5.0 mL) over 15 mins. The mixture was stirred at -78 °C for 6 h followed by room temperature overnight for 16 h and The mixture was stirred at -78 °C for 6 h followed by room temperature overnight for 16 h and TLC (30:70 EtOAc / hexane) showed absence of starting material (Rf=0.5) and a new spot for the product at Rf=0.57. The mixture was quenched with saturated NHC1 (25.0 ml), extracted with ethyl ether (3*30 mL) , washed with brine and dried (MgS0 4 ) . The solvent was stripped off in vacuo to afford crude product (1.3 g) as yellow oil and purified by flash column chromatography on a silica gel using 1:100 methanol / dichloromethane as eluent to afford desired product as pale yellow viscous oil (0.39 g, 32 %) . Mass spectrum (APcI-positive): m/z 403.3 (M+H + ) . The acetal was dissolved in acetone (15.0 mL) and treated with 3.0 M aqeous HC1 (30.0 mL) at room temperature. The reaction mixture was stirred for 24 h at this temperature and TLC (1:10 Me0H/CH 2 Cl 2 ) showed two new spots at Rf=0.92 & 0.62. It was then quenched with saturated NaCl (50.0 ml), extracted with ethyl acetate (3*50 mL) , washed with brine and dried (MgS0 4 ) . The solvent was removed in vacuum to afford yellow liquid and purified the crude by flash column chromatography on a silica gel using dichloromethane as eluent. to afford 0.17 g of desired product (Rf=0.62). Mass spectrum (CI- NH 3 ) : m/z 359 (M+H). 7-13-98: The above aldehyde (0.17 g) was dissolved in ethanol (15.0 mL) and treated with hydrazine (0.25 mL) . The mixture was refluxed overnight and TLC (1:10 MeOH/CH 2 Cl 2 ) revealed a new spot at Rf=0.49. The solvent was stripped off in vacuum and purified the crude by flash column chromatography on a silica gel using (1:50 MeOH/CH 2 Cl 2 ) as eluent to afford 84 mg colorless oil. The oil was crystallized from 1:10 hexane/ether to afford 64 mg of white solid (mp 126-127 °C) . HRMS calcd for C 20 H 27 N 4 O 2 : 355.2133. Found: 355.2121 (M+H) . Example 1124 4- (2, -dichlorophenyl) -2-ethyl-l- ( 1-ethyl ) propyl- 7-methylimidazo [4 , 5-d] pyridazine Part A: 4- (2 , 4-dichlorobenzoyl ) -2-ethyl- 1- ( 1- ethyl) propyl-5- ( 1-hydroxyethyl ) -IH-imidazole : A mixture of Part E material of Example 1 (0.587 g, 0.0016 moles) in THF (20 mL) was cooled to - 78 °C and then added dropwise 1.6 M MeLi in ether (1.0 mL, 0.0016 moles) over 5 mins. The mixture was stirred at -78 °C for 2 h and then quenched with water (5.0 ml) at -78 °C . The reaction mixture was extracted with ethyl ether (3*30 mL) , washed with brine and stripped off the solvent in vacuum to afford yellow liquid. TLC (30:70 EtOAc/hexane) showed absence of starting material at Rf=0.69 and a new spot at Rf=0.4. Purified the crude by flash column chromatography on a silica gel using 10 % EtOAC/hexane to afford 0.470 g (77 % yield) of desired product as white solid (mp 125-126 °C) . Mass spectrum (CI-NH 3 ): m/z=383 (M + ) . Anal, calcd for C 19 H 24 C1 2 N 2 0 2 : C, 59.54; H, 6.31; N, 7.32. Found: C, 59.59; H, 6.28; N,7.16. Part B: 5-Acetyl-4 -( 2 , 4-dichlorobenzoyl ) -2-ethyl- 1- ( l-ethyl)propyl-lH-imidazole A solution of Part A material of Example 1124 (0.4 g, 0.00104 moles) in toluene (10 mL) was treated with Mn0 2 (0.91 g, 0.0104 moles) and stirred at 75 °C for 40h. TLC (30:70 EtOAc/hexane) showed presence of starting material at Rf=0.4 and a new spot at Rf=0.57. Added additional Mn0 2 (0.91 g) and continued for addtional 20 h at 75 °C. &- 27-98: TLC revealed only trace amount of starting material and therefore cooled the reaction mixture to room temp and filtered through celite. The filterate was concentrated to afford 0.32 g of colorless oil and purified the crude by flash column chromatography on a silica gel using 15 % EtOAC/hexane to afford 0.258 g (65 % yield) of desired product as white solid (m.p. 63-64 °C) . Mass spec (CI-NH 3 ) : m/z=381 (M + ) . Anal, calcd. for Cι 9 H 22 Cl 2 N 2 0 2 : C, 59.85; H, 5.83; N, 7.36. Found: C, 59.97; H,5.80; N, 7.12. Part C: Title Compound: imidazole A solution of Part B material of Example 1124 (0.130 g, 0.00034 moles) in ethanol (10 mL) was treated with anhydrous hydrazine (0.142 g, 0.0044 moles) and refluxed under nitrogen for 3h. TLC (1:10 MeOH / CH 2 C1 2 ) showed a new spot at Rf=0.55. The solvent was removed under vacuum and purified the crude by flash column chromatography on a silica gel using 50:50 EtOAc / hexane to afford 53 mg (41 % yield) of the product as white solid after tituration of the oil with diethyl ether (mp 128-129 °C) . Mass spectrum (CI-NH 3 ) : m/z 377 (M + ) . Anal, calcd. for Cι 9 H 22 Cl 2 N 4 : C, 60.48; H, 5.89; N, 14.89. Found: C, 59.40; H, 5.72; N, 14.46. Example 1125 4- (2, 4-dichlorophenyl) -2-ethyl-l- ( 1-ethyl )propyl- 7-propoxyimidazo [4 , 5-d] pyridazine Part A: Methyl 4- (2 , 4-dichlorobenzoyl ) -2-ethyl-l- (l-ethyl)propyl-lH-imidazole- 5-carboxalate: A mixture of Part E material of Example 1 (0.367 g, 0.001 moles) in methanol (60 mL) was treated with NaCN (Aldrich, 0.245 g, 0.005 moles, 5 equi.), AcOH (Baker, 96 mg; 0.0016 moles, 1.6 equiv. ) and Mn0 2 , activated (Aldich, 1.24 g, 0.021 moles, 21 equiv. ) . The resulting mixture was stirred at room temp under nitrogen for 18 h. TLC (1:50 MeOH/CH 2 Cl 2 ) revealed absence of starting material at Rf=0.8 and showed a new spot at Rf=0.44. Mass spec, revealed desired product (m/z=397) . The reaction mixture was filtered through celite, washed with methanol, concentrated in vacuo and the crude was purified by flash column chromatography on a silica gel using 1:100 MeOH/CH 2 Cl 2 as eluent to afford 320 mg (mp 73-74 °C, 81 %) of white solid after crystallization from hexane. Anal. calcd. for C 19 H 22 N 2 0 3 C1 2 : C, 57.44; H,5.58; N,7.05. Found: C57.31; H,5.45; N, 6.85. Part B: 4- ( 2 , 4-dichlorophenyl ) -2-ethyl- 1- ( 1- ethyl) propyl-imidazo [4, 5-d] pyridazin-7-one: A mixture of Part A material of example 1125 (0.100 g, 0.00025 moles) in ethanol (10 mL) was treated with anhydrous hydrazine (0.105 g, 0.0033 moles) and refluxed under nitrogen for 48 h. TLC (30:70 EtOAc/hexane) showed a new spot at Rf=0.35. The solvent was removed under vacuum and purified the crude by flash column chromatography on a silica gel using 15:50 EtOAc / hexane intially and then methanol to afford 70 mg (74 % yield) of the product as white solid after tituration of the oil with diethyl ether (mp 246-247 °C) . Mass spectrum (CI-NH 3 ) m/z=379 (M + ) . Part C: Title Compound: A mixture of Part B material of example 1125 (0.1 g, 0.264 mmol) in benzene (5.0 mL) was treated with n-BuNBr (8.5 mg, 0.0264 mmol), powdered KOH (15 mg, 0.264 mmol) and 1- iodopropane (0.134 g, 0.79 mmol). The mixture was stirred at room temp overnight and TLC (1:50 MeOH/CH 2 Cl 2 ) showed two new spots at Rf=0.73 and Rf=0.46. The reaction mixture was diluted with EtOAc (10 mL) , washed with brine (10 mL) , dried with MgS0 and concentrated to a residue. The crude was purified by flash column chromatography on a silica gel using dichloromethane as eluent to afford 56 mg (51 % yield) of the N-propyl product as colorless oil . Mass spectrum (CI-NH 3 ) : m/z=421. Further elution of the column with 1:50 MeOH/CH 2 Cl 2 gave 11 mg (10 % yield) of oil which was crystallized from ether to afford 7-propoxy derivative as awhite solid (m.p. 120-121 °C) . Mass spec. (CI-NH 3 ) : m/z=421. HRMS calcd for C 21 H 27 N 4 0C1 2 : 421.1561. Found: 421.1569 (M+H) . Example 1126 7-chloro-4- ( 2 , 4-dichlorophenyl ) -2-ethyl-l- (1- methyl) butyl- imidazo [4, 5-d] pyridazine Part A: 4 , 5-dibromo-2-ethyl-l- ( 1-methyl ) butyl- 1H- imidazole : A mixture of part A material of example 1 (59 g g, 0.233 moles), triphenylphosphine (67.1 g, 0.256 moles) and molecular sieves (10 g) in THF (715 mL) was cooled to 0 to - 5 °C and then added 2-pentanol (34.79 g, 0.279 moles) under nitrogen atmosphere. The mixture was stirred at 0 °C for 30 mins and then added disopropylazodicarboxylate (50.33 g, 0.256 moles) dropwise over 20 mins. The mixture was stirred at 0 °C for 2h followed by room temperature for 2 days and TLC (1:50 MeOH / CH 2 C1 2 ) revealed a new spot at Rf=0.5. The undissolved material was filtered, washed with dichloromethane and stripped off the solvent in vacuum to afford yellow liquid. The crude was purified by flash column chromatography using chloroform as eluent to afford 41.5 g (55 %) of colorless oil. λ E NMR (CDC1 3 ) : ? 0.91 (t, 3H, 2*CH 3 ), 1.27 (m, 2H, CH 2 ) , 1.31 (t, 3H, CH 3 ), 1.53 (d, 3H, CH 3 ), 1.78 (m, IH) , 2.04 (m, IH) , 2.71 (q, 2H) and 4.34 (m,lH). Mass spectrum (CI-NH 3 ) : m/z 325.0 (M+H) . Part B: 4-bromo-2-ethyl-l- ( 1-methyl ) butyl- 1H- imidazole-5-carboxaldehyde : A solution of imidazole (37.5 g, 0.116 mol) in THF (250 mL) was cooled to -78 °C and then added dropwise 1.6 M n-BuLi(76 mL, 0. 122 mol) in hexane over 45 mins. The mixture was stirred at -78 °C for lh (brown solution) and then added DMF (27 g, 0.348 moles) dropwise over 30 mins. The mixture was stirred at -78 °C for 60 mins. The reaction mixture was quenched with satd. amm. chloride (100 mL) at -78 °C and brought to room temp. The reaction mixture was extracted with ethyl ether (3*100 mL) , washed with brine and dried with anhyd. MgS0 4 . The solvent was evaporated under reduced pressure to afford 31.6 g of crude yellow oil. The NMRof the crude revealed formation of 4-bromo-2-ethyl-1- (1-methyl) butyl-1H- imidazole along with desired product in the ratio of 3:7. The TLC of the undesired 4-bromo-2-ethyl-1- (1- methyl) butyl-IH-imidazole is visible under iodine exposure (Rf=0.45). The crude was purified by flash column chromatography on a silica gel using 1% MeOH to afford 18.5 g (59 % yield) of colorless oil. Mass spec : m/z=273. Anal, calcd. for C u H 17 N 2 OBr; C, 48.36; H, 6.27, N, 10.25. Found): C, 48.64; H, 6.01; N, 10.00. Part C: 4-bromo-2-ethyl- 1- ( 1-methyl ) butyl- 1H- imidazole-5-carboxaldehyde ethylene acetal: A mixture of Part B material of example 1126 (18.5 g, 0.068 moles) in benzene (250 mL) was treated with ethylene glycol (16.4 g, 0.264 moles), pyridine (2.7 g, 0.034 moles) and p-toluenesulfonic acid monohydrate (6.5 g, 0.034 moles). The reaction mixture was heated at reflux in a 20 mL capacity Dean-Stark trap equipped apparatus for 36h. TLC (30:70 EtOAc/hexane) revealed a new spot at Rf=0.42 (visible under iodine) along with trace amount of starting material (Rf=0.54). The reaction mixture was cooled to room temperature, diluted with EtOAc (250 mL) , washed with 10 % sodium bicarbonate (2*250 mL) , brine and dried (MgS0) . The solvent was evaporated under reduced pressure to furnish white solid (20.7 g, mp 69-70 °C, 96 %) . The crude was very pure by NMR. Mass spectrum (CI-NH 3 ) : m/z 317.1 (M + ) . Anal, calcd. for Ci3H22N202Bri; C, 49.22; H, 6.67, N, 8.83. Found: C, 49.38; H, 6.62; N, 8.68. Part D: 4- (2 , 4-dichlorobenzoyl ) -2-ethyl- 1- ( 1- methyl )butyl-lH-imidazole- 5-carboxaldehyde: A solution of Part C material of Example 1126 (2.3 g, 5.6 mmol) in acetone (60 mL) was cooled to 15 °C and then added 3M aq. HC1 (120 mL) over 15 mins. The mixture was stirred below 30 °C for 24 h. TLC (30:70 EtOAc/hexane) showed a new spot at Rf=0.58 along with disappearence of starting material (Rf=0.43). The solvent was removed under vacuum, extracted with ethyl acetate (3*50 mL) , washed with brine and stripped off the solvent in vacuum to afford yellow liquid (2.4 g) . The crude was purified by flash column chromatography on a silica gel using dichloromethane as eluent to afford 1.46 g (71 % yield) of desired product as yellow solid (mp 43-44 °C) . Anal. calcd for Cι 8 H 20 Cl 2 N 2 O 2 : C, 58.87; H, 5.50; N, 7.64. Found: C, 58.96; H, 5.34; N, 7.46. Mass spec. (NH 3 -CI) : m/z=367 Part E: Methyl 4- ( 2 , 4-dichlorobenzoyl ) -2-ethyl- 1- ( l-methyl)butyl-lH-imidazole- 5-carboxalate: A mixture of Part D material of Example 1126 (1.0 g, 0.0027 moles) in methanol (50 mL) was treated with NaCN (Aldrich, 0.67 g, 0.0136 moles, 5 equi.), AcOH (Baker, 260 mg; 0.00432 moles, 1.6 equiv.) and Mn0 2 , activated (Aldrich, 3.34 g, 0.057 moles, 21 equiv. ) . The resulting mixture was stirred at room temp under nitrogen for 20 h. TLC (30:70 EtOAc/hexane) revealed absence of starting material at Rf=0.58 and showed a new spot at Rf=0.4. The reaction mixture was filtered through celite, washed with methanol, concentrated in vacuo. The residue was diluted with water, extracted with ethyl acetate, washed with brine, dried and concentrated in vacuo to afford 0.98 g of yellow oil. The crude was purified by flash column chromatography on a silica gel using 30:70 EtOAc/hexane as eluent to afford 910 mg (85 %) of yellow oil. Mass spectrum : m/z=397. Anal, calcd. for C 19 H 22 N 2 0 3 C1 2 : C, 57.44; H, 5.58; N, 7.05. Found: C, 57.25; H, 5.70; N, 6.80. Part P : 4 - ( 2 , 4 - dichlorophenyl ) - 2 - ethyl - 1- ( 1 - ethyl ) propyl - imidazo [4 , 5 - d] pyridaz in- 7 - one : A mixture of Part E material of Example 1126 ( 0 . 460 g, 0.00115 moles) in ethylene glycol (5 mL) was treated with anhydrous hydrazine (0.48 g, 0.0151 moles) and refluxed under nitrogen for 4h. TLC (30:70 EtOAc/hexane) revealed a new spot (Rf=0.44) along with disappearence of starting material (Rf=0.4). The reaction mixture was cooled to room temp and poured over 25 mL of water, extracted with EtOAc (3*15 mL) , washed with brine and dried. The solvent was removed under vacuo and purified the crude by flash column chromatography on a silica gel using 15 % EtOAc/hexane to afford colorless oil which was crystallized from hexane to afford 310 mg of white solid (71 %, mp 217-18 °C) . Mass spec. (CI-NH 3 ) : m/z=379. Anal. calcd. for C 18 H 2 oN 4 Cl 2 0: C, 57.00; H, 5.33; N, 14.77. Found: C, 57.02; H, 5.35; N, 14.59. Part G: Title Compound: A mixture of Part F material of Example 1126 (0.270 g, 0.0071moles) in P0C1 3 (3.0 mL) was refluxed under nitrogen for 8 h. TLC (30:70 EtOAc/hexane) revealed a new spot (Rf=0.48) along with disappearence of starting material (Rf=0.44) Excess POCl 3 from the reaction mixture was removed under vacuo, quenched with ice (10 g) , extracted with EtOAc (3*15 mL) , washed with brine and dried. The solvent was removed under vacuo and purified the crude by flash column chromatography on a silica gel using 30 % EtOAc/hexane to afford 80 mg of white solid (28 %, mp 124-125 °C) . HRMS calcd for C 18 H 2 oN 4 Cl 3 : 397.0753. Found: 397.0749 (M+H) . Example 1127 4- (2, 4-dichlorophenyl) -2-ethyl-l- ( 1-methyl ) butyl- 7 -methoxy- imidazo [4, 5-d] pyridazine A mixture of Part G material of Example 1126 (40 mg, 0.1 mmole) in MeOH (3.0 mL) was treated with 25 % NaOMe in MeOH (0.065 mL, 0.3 mmole) and refluxed under nitrogen for 6 h. TLC (30:70 EtOAc/hexane) revealed a new spot (Rf=0.35) along with disappearence of starting material (Rf=0.48). The solvent from the reaction mixture was removed under vacuo, quenched with water (10 g) , extracted with EtOAc (3*15 mL) , washed with brine and dried. The solvent was removed under vacuo and purified the crude by recrystallizing from hexane to afford 36 mg of white solid (92 %, mp 119-120 °C) . HRMS calcd for C 19 H 23 NCI 3 O 1 : 393.1248. Found: 393.1246 (M+H). Table 1 a 2 R 2 X=CH 3 S b 2 R 2 X=CH 3 S c 2 R 2 X=CH 3 S a 3 R 2 X=Me b 3 R 2 X=Me c 3 R 2 X=Me a 4 R 2 X=Et b 4 R 2 X=Et c 4 R 2 X=Et a 5 R 2 X=n-Pr b 5 R 2 X=n-Pr c 5 R 2 X=n-Pr d 2 R 2 X=CH 3 S e 2 R 2 X=CH 3 S f 2 R 2 X=CH 3 S d 3 R 2 X=Me e 3 R 2 X=Me f 3 R 2 X=Me d 4 R 2 X=Et e 4 R 2 X=Et f Δ R 2 X=Et d 5 R 2 X=n-Pr e 5 R 2 X=n-Pr R^X= Ω-Pr g 2 R 2 X==CH 3 S g 3 R 2 X=Me g 4 R 2 X=Et g 5 R 2 X=n-Pr Ex. # R1 D la (cPr)2CH phenyl 2 phenyl (cPr)CH phenyl 3 2-furanyl (cPr)CH phenyl 4 3-furan(cPr)CH phenyl 2-thienyl(cPr)CH phenyl 3-thienyl(cPr)CH phenyl 2-isoxazolyl (cPr) CH phenyl 2- (5-CH3-furanyl) (cPr)CH phenyl 2-(4-CH3-isoxazolyl) (cPr)CH phenyl cPr-CH(CH3) phenyl l-cPr-CH(CH2CH3) phenyl 1-cPr-CH (CH2CH2CH3 ) phenyl l-cPr-CH(CH20CH3) phenyl 1-cPr-CH (CH2CH2OCH3 ) phenyl (cBu)2CH phenyl phenyl (cBu)CH phenyl 2-furanyl (cBu)CH phenyl 3-furan(cBu)CH phenyl 2-thienyl (cBu)CH phenyl 3-thienyl(cBu)CH phenyl 2-isoxazolyl (cBu) CH phenyl 2- (5-CH3-furanyl) (cBu)CH phenyl 2-(4-CH3-isoxazolyl) (cBu)CH phenyl cBu-CH(CH3) phenyl l-cBu-CH(CH2CH3) phenyl 1-cBu-CH (CH2CH2CH3 ) phenyl l-cBu-CH(CH20CH3) phenyl 1-cBu-CH (CH2CH2OCH3 ) phenyl (cPr)2CH 2-Cl-4-MeO- -phenyl phenyl (cPr)CH 2-Cl-4-MeO- -phenyl 2-furanyl (cPr)CH 2-Cl-4-MeO- -phenyl 3-furan(cPr)CH 2-Cl-4-MeO- -phenyl 2-thienyl(cPr)CH 2-Cl-4-MeO- -phenyl 3-thienyl(cPr)CH 2-Cl-4-MeO- -phenyl 2-isoxazolyl (cPr) CH 2-Cl-4-MeO- -phenyl 2- (5-CH3-furanyl) (cPr)CH 2-Cl-4-MeO- -phenyl 2-(4-CH3-isoxazolyl) (cPr)CH 2-Cl-4-MeO- -phenyl cPr-CH(CH3) 2-Cl-4-MeO- -phenyl l-cPr-CH(CH2CH3) 2-Cl-4-MeO- -phenyl 1-cPr-CH (CH2CH2CH3 ) 2-Cl-4-MeO- -phenyl l-cPr-CH(CH20CH3) 2-Cl-4-MeO- -phenyl 1-cPr-CH (CH2CH2OCH3 ) 2-Cl-4-MeO- -phenyl (cBu)2CH 2-Cl-4-MeO-phenyl phenyl (cBu)CH 2-Cl-4-MeO-phenyl 2- furanyl (cBu)CH 2-Cl-4-MeO-phenyl 3-furan(cBu)CH 2-Cl-4-MeO-phenyl 2-thienyl(cBu)CH 2-Cl-4-MeO-phenyl 3-thienyl(cBu)CH 2-Cl-4-MeO-phenyl 2-isoxazolyl (cBu) CH 2-Cl-4-MeO-phenyl 2- (5-CH3 -furanyl) (cBu)CH 2-Cl-4-MeO-phenyl 2-(4-CH3-isoxazolyl) (cBu)CH 2-Cl-4-MeO-phenyl cBu-CH(CH3) 2-Cl-4-MeO-phenyl l-cBu-CH(CH2CH3) 2-Cl-4-MeO-phenyl 1-cBu-CH (CH2CH2CH3 ) 2-Cl-4-MeO-phenyl l-cBu-CH(CH20CH3) 2-Cl-4-MeO-phenyl 1-cBu-CH (CH2CH2OCH3 ) 2-cl-4-MeO-phenyl (cPr)2CH 2 -CI-4-CF3 -phenyl phenyl (cPr)CH 2 -CI-4-CF3 -phenyl 2- furanyl (cPr)CH 2-Cl-4-CF3-phenyl 3-furan(cPr)CH 2 -CI-4-CF3 -phenyl 2-thienyl(cPr)CH 2-Cl-4-CF3-phenyl 3-thienyl(cPr)CH 2-Cl-4-CF3-phenyl 2 - isoxazolyl ( cPr ) CH 2-Cl-4-CF3-phenyl 2- (5-CH3 -furanyl) (cPr)CH 2 -CI-4-CF3 -phenyl 2-(4-CH3-isoxazolyl) (cPr)CH 2-Cl-4-CF3-phenyl cPr-CH(CH3) 2 -CI-4-CF3 -phenyl l-cPr-CH(CH2CH3) 2 -CI-4-CF3 -phenyl 1-cPr-CH (CH2CH2CH3 ) 2 -CI-4-CF3 -phenyl l-cPr-CH(CH20CH3) 2-Cl-4-CF3-phenyl 1-cPr-CH (CH2CH2OCH3 ) 2 -CI-4-CF3 -phenyl (cBu)2CH 2-Cl-4-CF3-phenyl phenyl (cBu)CH 2-Cl-4-CF3-phenyl 2-furanyl(cBu)CH 2-Cl-4-CF3-phenyl 3-furan(cBu)CH 2 -CI-4-CF3 -phenyl 2-thienyl(cBu)CH 2-Cl-4-CF3-phenyl 3-thienyi(cBu)CH 2-Cl-4-CF3-phenyl 2-isoxazolyl (cBu) CH 2-Cl-4-CF3-phenyl 2- (5-CH3- furanyl) (cBu)CH 2-Cl-4-CF3-phenyl 2-(4-CH3-isoxazolyl) (cBu)CH 2-Cl-4-CF3-phenyl cBu-CH(CH3) 2-Cl-4-CF3-phenyl 81 l-cBu-CH(CH2CH3) 2--CI-4-CF3-phenyl 82 l-cBu-CH(CH2CH2CH3) 2- -CI-4-CF3-phenyl 83 l-cBu-CH(CH20CH3) 2- -CI-4-CF3-phenyl 84 1-cBu-CH (CH2CH2OCH3 ) 2- -CI-4-CF3-phenyl 85 (cPr)2CH 2 , 4-diCl-phenyl 86 phenyl (cPr)CH 2 , 4-diC1-phenyl 87 2-furanyl (cPr)CH 2 4-diC1-phenyl 88 3-furan(cPr)CH 2 4-diCl-phenyl 89 2-thienyl(cPr)CH 2 4-diCl-phenyl 90 3-thienyl(cPr)CH 2 4-diCl-phenyl 91 2-isoxazolyl (cPr) CH 2 4-diC1-phenyl 92 2- (5-CH3-furanyl) (cPr)CH 2 4-diC1-phenyl 93 2-(4-CH3-isoxazolyl) (cPr)CH 2 4-diC1-phenyl 94 cPr-CH(CH3) 2 4-diC1-phenyl 95 l-cPr-CH(CH2CH3) 2 4-diCl-phenyl 96 l-cPr-CH(CH2CH2CH3) 2 4-diCl-phenyl 97 l-cPr-CH(CH20CH3) 2 4-diCl-phenyl 98 1-cPr-CH (CH2CH2OCH3 ) 2 4-diC1-phenyl 99 (cBu)2CH 2 4-diCl-phenyl 100 phenyl (cBu)CH 2 4-diC1-phenyl 101 2-furanyl (cBu)CH 2 4-diC1-phenyl 102 3-furan(cBu)CH 2 4-diCl-phenyl 103 2-thienyl (cBu)CH 2 4-diCl-phenyl 104 3-thienyl (cBu)CH 2 4-diCl-phenyl 105 2-isoxazolyl (cBu) CH 2 4-diCl-phenyl 106 2- (5-CH3-furanyl) (cBu)CH 2 4-diC1-phenyl 107 2-(4-CH3-isoxazolyl) (cBu)CH 2 4-diCl-phenyl 108 cBu-CH(CH3) 2 4-diCl-phenyl 109 l-cBu-CH(CH2CH3) 2 4-diCl-phenyl 110 l-cBu-CH(CH2CH2CH3) 2 4-diCl-phenyl 111 l-cBu-CH(CH20CH3) 2 4-diC1-phenyl 112 1-cBu-CH (CH2CH2OCH3 ) 2 4-diC1-phenyl 113 (cPr)2CH 2 5-diC1-phenyl 114 phenyl (cPr)CH 2 5-diCl-phenyl 115 2-furanyl(cPr)CH 2 5-diCl-phenyl 116 3-furan(cPr)CH 2 5-diC1-phenyl 117 2-thienyl(cPr)CH 2 5-diCl-phenyl 118 3-thienyl(cPr)CH 2 5-diCl-phenyl 119 2-isoxazolyl (cPr)CH 2, 5-diC1-phenyl 120 2- (5-CH3-1uranyl ) (cPr)CH 2,5-diCl-phenyl 121 2-(4-CH3-isoxazolyl) (cPr)CH 2,5-diCl-phenyl 122 cPr-CH(CH3) 2,5-diCl-phenyl 123 l-cPr-CH(CH2CH3) 2, 5-diCl-phenyl 124 l-cPr-CH(CH2CH2CH3) 2,5-diCl-phenyl 125 l-cPr-CH(CH20CH3) 2,5-diCl-phenyl 126 l-cPr-CH(CH2CH20CH3) 2 , 5-diCl-phenyl 127 (cBu)2CH 2,5-diCl-phenyl 128 phenyl (cBu)CH 2, 5-diCl-phenyl 129 2-furanyl (cBu)CH 2,5-diCl-phenyl 130 3-furan(cBu)CH 2,5-diCl-phenyl 131 2-thienyl(cBu)CH 2, 5-diCl-phenyl 132 3-thienyl(cBu)CH 2, 5-diCl-phenyl 133 2-isoxazolyl (cBu)CH 2,5-diCl-phenyl 134 2- (5-CH3-furanyl ) (cBu)CH 2, 5-diCl-phenyl 135 2-(4-CH3-isoxazolyl) (cBu)CH 2, 5-diCl-phenyl 136 cBu-CH(CH3) 2,5-diCl-phenyl 137 l-cBu-CH(CH2CH3) 2,5-diCl-phenyl 138 l-cBu-CH(CH2CH2CH3) 2 , 5-diCl-phenyl 139 l-cBu-CH(CH20CH3) 2,5-diCl-phenyl 140 l-cBu-CH(CH2CH20CH3) 2,5-diCl-phenyl 141 (cPr)2CH 2-Cl-4-CF3θ-phenyl 142 phenyl (cPr)CH 2-Cl-4-CF3θ-phenyl 143 2-furanyl(cPr)CH 2-Cl-4-CF3θ-phenyl 144 3-furan(cPr)CH 2-Cl-4-CF3θ-phenyl 145 2-thienyl(cPr)CH 2-Cl-4-CF3θ-phenyl 146 3-thienyl(cPr)CH 2-Cl-4-CF3θ-phenyl 147 2-isoxazolyl (cPr) CH 2-Cl-4-CF3θ-phenyl 148 2- (5-CH3-1uranyl ) (cPr)CH 2-Cl-4-CF3θ-phenyl 149 2-(4-CH3-isoxazolyl) (cPr)CH 2-Cl-4-CF3θ-phenyl 150 cPr-CH(CH3) 2-Cl-4-CF3θ-phenyl 151 l-cPr-CH(CH2CH3) 2-Cl-4-CF3θ-phenyl 152 l-cPr-CH(CH2CH2CH3) 2-Cl-4-CF3θ-phenyl 153 l-cPr-CH(CH20CH3) 2-Cl-4-CF3θ-phenyl 154 l-cPr-CH(CH2CH20CH3) 2-Cl-4-CF3θ-phenyl 155 (cBu)2CH 2-Cl-4-CF3θ-phenyl 156 phenyl (cBu)CH 2-Cl-4-CF3θ-phenyl 157 2- furanyl (cBu)CH 2-Cl-4-CF3θ-phenyl 158 3-furan(cBu)CH 2-Cl-4-CF3θ-phenyl 159 2 - thienyl (cBu)CH 2-Cl-4-CF3θ-phenyl 160 3 - thienyl (cBu)CH 2-Cl-4-CF3θ-phenyl 161 2-isoxazolyl (cBu) CH 2-Cl-4-CF3θ-phenyl 162 2- (5-CH3- furanyl) (cBu)CH 2-Cl-4-CF3θ-phenyl 163 2-(4-CH3-isoxazolyl) (cBu)CH 2-Cl-4-CF3θ-phenyl 164 cBu-CH(CH3) 2-Cl-4-CF3θ-phenyl 165 l-cBu-CH(CH2CH3) 2-Cl-4-CF3θ-phenyl 166 l-cBu-CH(CH2CH2CH3) 2-Cl-4-CF3θ-phenyl 167 l-cBu-CH(CH20CH3) 2-Cl-4-CF3θ-phenyl 168 1-cBu-CH (CH2CH2OCH3 ) 2-Cl-4-CF3θ-phenyl 169 (cPr)2CH 2 -CI-4-CH3 -phenyl 170 phenyl (cPr)CH 2-Cl-4-CH3-phenyl 171 2- f uranyl (cPr)CH 2-Cl-4-CH3-phenyl 172 3-furan(cPr)CH 2 -CI-4-CH3 -phenyl 173 2-thienyl(cPr)CH 2-Cl-4-CH3-phenyl 174 3-thienyl(cPr)CH 2 -CI-4-CH3 -phenyl 175 2-isoxazolyl (cPr) CH 2-Cl-4-CH3-phenyl 176 2- (5-CH3- furanyl) (cPr)CH 2 -CI-4-CH3 -phenyl 177 2-(4-CH3-isoxazolyl) (cPr)CH 2 -CI-4-CH3 -phenyl 178 cPr-CH(CH3) 2-Cl-4-CH3-phenyl 179 l-cPr-CH(CH2CH3) 2 -CI-4-CH3 -phenyl 180 l-cPr-CH(CH2CH2CH3) 2-Cl-4-CH3-phenyl 181 l-cPr-CH(CH20CH3) 2 -CI-4-CH3 -phenyl 182 1-cPr-CH (CH2CH2OCH3 ) 2-Cl-4-CH3-phenyl 183 (cBu)2CH 2-Cl-4-CH3-phenyl 184 phenyl (cBu)CH 2 -CI-4-CH3 -phenyl 185 2- furanyl (cBu)CH 2 -CI-4-CH3 -phenyl 186 3-furan(cBu)CH 2 -CI-4-CH3 -phenyl 187 2-thienyl(cBu)CH 2 -CI-4-CH3 -phenyl 188 3-thienyl(cBu)CH 2-Cl-4-CH3-phenyl 189 2-isoxazolyl (cBu) CH 2 -CI-4-CH3 -phenyl 190 2- (5-CH3-E uranyl) (cBu)CH 2-Cl-4-CH3-phenyl 191 2-(4-CH3-isoxazolyl) (cBu)CH 2 -CI-4-CH3 -phenyl 192 cBu-CH(CH3) 2 -CI-4-CH3 -phenyl 193 l-cBu-CH(CH2CH3) 2 -CI-4-CH3 -phenyl 194 l-cBu-CH(CH2CH2CH3) 2-Cl-4-CH3-phenyl 195 l-cBu-CH(CH20CH3) 2-CI-4-CH3-phenyl 196 1-cBu-CH (CH2CH2OCH3 ) 2-Cl-4-CH3-phenyl 197 (cPr)2CH 2-C1-4-CN-phenyl 198 phenyl (cPr)CH 2-Cl-4-CN-phenyl 199 2-furanyl(cPr)CH 2-C1-4-CN-phenyl 200 3-furan(cPr)CH 2-C1-4-CN-phenyl 201 2-thienyl(cPr)CH 2-Cl-4-CN-phenyl 202 3-thienyl(cPr)CH 2-C1-4-CN-phenyl 203 2-isoxazolyl (cPr) CH 2-Cl-4-CN-phenyl 204 2- (5-CH3-furanyl) (cPr)CH 2-Cl-4-CN-phenyl 205 2-(4-CH3-isoxazolyl) (cPr)CH 2-C1-4-CN-phenyl 206 cPr-CH(CH3) 2-Cl-4-CN-phenyl 207 l-cPr-CH(CH2CH3) 2-C1-4-CN-phenyl 208 1-cPr-CH (CH2CH2CH3 ) 2-C1-4-CN-phenyl 209 l-cPr-CH(CH20CH3) 2-Cl-4-CN-phenyl 210 l-cPr-CH(CH2CH20CH3) 2-C1-4-CN-phenyl 211 (cBu)2CH 2-C1-4-CN-phenyl 212 phenyl (cBu)CH 2-Cl-4-CN-phenyl 213 2-furanyl (cBu)CH 2-Cl-4-CN-phenyl 214 3-furan(cBu)CH 2-C1-4-CN-phenyl 215 2-thienyl(cBu)CH 2-C1-4-CN-phenyl 216 3-thienyl(cBu)CH 2-Cl-4-CN-phenyl 217 2-isoxazolyl (cBu) CH 2-C1-4-CN-phenyl 218 2- (5-CH3-furanyl) (cBu)CH 2-Cl-4-CN-phenyl 219 2-(4-CH3-isoxazolyl) (cBu)CH 2-Cl-4-CN-phenyl 220 cBu-CH(CH3) 2-Cl-4-CN-phenyl 221 l-cBu-CH(CH2CH3) 2-Cl-4-CN-phenyl 222 l-cBu-CH(CH2CH2CH3) 2-C1-4-CN-phenyl 223 l-cBu-CH(CH20CH3) 2-Cl-4-CN-phenyl 224 1-cBu-CH (CH2CH2OCH3 ) 2-C1-4-CN-phenyl 225 (cPr)2CH 2-CF3-4-Cl-phenyl 226 phenyl (cPr)CH 2-CF3-4-Cl-phenyl 227 2-furanyl (cPr)CH 2-CF3-4-Cl-phenyl 228 3-furan(cPr)CH 2-CF3-4-Cl-phenyl 229 2-thienyl(cPr)CH 2-CF3-4-Cl-phenyl 230 3-thienyl(cPr)CH 2-CF3-4-Cl-phenyl 231 2-isoxazolyl (cPr) CH 2-CF3-4-Cl-phenyl 232 2- (5-CH3-furanyl) (cPr)CH 2-CF3-4-Cl-phenyl 233 2-(4-CH3-isoxazolyl) (cPr)CH 2-CF3-4-Cl-phenyl 234 cPr-CH(CH3) 2-CF3-4-Cl-phenyl 235 l-cPr-CH(CH2CH3) 2-CF3-4-Cl-phenyl 236 1-cPr-CH (CH2CH2CH3 ) 2-CF3-4-Cl-phenyl 237 l-cPr-CH(CH20CH3) 2-CF3-4-Cl-phenyl 238 1-cPr-CH (CH2CH2OCH3 ) 2-CF3-4-Cl-phenyl 239 (cBu)2CH 2-CF3-4-Cl-phenyl 240 phenyl (CBu) CH 2-CF3-4-Cl-phenyl 241 2- furanyl (cBu)CH 2-CF3-4-Cl-phenyl 242 3-furan(cBu)CH 2-CF3-4-Cl-phenyl 243 2-thienyl(cBu)CH 2-CF3-4-Cl-phenyl 244 3-thienyl(cBu)CH 2-CF3-4-Cl-phenyl 245 2-isoxazolyl (cBu) CH 2-CF3-4-Cl-phenyl 246 2- (5-CH3- furanyl) (cBu)CH 2-CF3-4-Cl-phenyl 247 2-(4-CH3-isoxazolyl) (cBu)CH 2-CF3-4-Cl-phenyl 248 cBu-CH(CH3) 2-CF3-4-Cl-phenyl 249 l-cBu-CH(CH2CH3) 2-CF3-4-Cl-phenyl 250 l-cBu-CH(CH2CH2CH3) 2-CF3-4-Cl-phenyl 251 l-cBu-CH(CH20CH3) 2-CF3-4-Cl-phenyl 252 1-cBu-CH (CH2CH2OCH3 ) 2-CF3-4-Cl-phenyl 253 (cPr)2CH 2 -CF3 -4-MeO-phenyl 254 phenyl (cPr)CH 2-CF3-4-MeO-phenyl 255 2- furanyl (cPr)CH 2-CF3-4-MeO-phenyl 256 3-furan(cPr)CH 2-CF3-4-MeO-phenyl 257 2-thienyl(cPr)CH 2 -CF3 - 4-MeO-phenyl 258 3-thienyi(cPr)CH 2-CF3-4-MeO-phenyl 259 2-isoxazolyl (cPr) CH 2-CF3-4-MeO-phenyl 260 2- (5-CH3- furanyl) (cPr)CH 2-CF3-4-MeO-phenyl 261 2-(4-CH3-isoxazolyl) (cPr)CH 2-CF3-4-MeO-phenyl 262 cPr-CH(CH3) 2-CF3-4-MeO-phenyl 263 l-cPr-CH(CH2CH3) 2-CF3-4-MeO-phenyl 264 1-cPr-CH (CH2CH2CH3 ) 2-CF3-4-MeO-phenyl 265 l-cPr-CH(CH20CH3) 2-CF3-4-MeO-phenyl 266 1-cPr-CH (CH2CH2OCH3 ) 2-CF3-4-MeO-phenyl 267 (cBu)2CH 2-CF3-4-MeO-phenyl 268 phenyl (cBu)CH 2-CF3-4-MeO-phenyl 269 2- furanyl (cBu)CH 2-CF3-4-MeO-phenyl 270 3-furan(cBu)CH 2-CF3-4-MeO-phenyl 271 2-thienyl (cBu)CH 2-CF3 -4-MeO-phenyl 272 3-thienyl(cBu)CH 2-CF3 -4-MeO-phenyl 273 2-isoxazolyl (cBu) CH 2-CF3 -4-MeO-phenyl 274 2- (5-CH3-furanyl) (cBu)CH 2-CF3 -4-MeO-phenyl 275 2-(4-CH3-isoxazolyl) (cBu)CH 2-CF3 -4-MeO-pheny1 276 cBu-CH(CH3) 2-CF3 -4-MeO-phenyl 277 l-cBu-CH(CH2CH3) 2-CF3 -4-MeO-phenyl 278 l-cBu-CH(CH2CH2CH3) 2-CF3 -4-MeO-pheny1 279 l-cBu-CH(CH20CH3) 2-CF3 -4-MeO-phenyl 280 1-cBu-CH (CH2CH2OCH3 ) 2-CF3 -4-MeO-phenyl 281 (cPr)2CH 2-CF3 -4-n-PrO-phenyl 282 phenyl (cPr)CH 2-CF3 -4-n-PrO-phenyl 283 2-furanyl (cPr)CH 2-CF3 -4-n-PrO-phenyl 284 3-furan(cPr)CH 2-CF3 -4-n-PrO-phenyl 285 2-thienyl(cPr)CH 2-CF3 -4-n-PrO-phenyl 286 3-thienyl(cPr)CH 2-CF3 -4-n-PrO-phenyl 287 2-isoxazolyl (cPr) CH 2-CF3 -4-n-PrO-phenyl 288 2- (5-CH3-furanyl) (cPr)CH 2-CF3 -4-n-PrO-phenyl 289 2-(4-CH3-isoxazolyl) (cPr)CH 2-CF3 -4-n-PrO-phenyl 290 cPr-CH(CH3) 2-CF3 -4-n-PrO-phenyl 291 l-cPr-CH(CH2CH3) 2-CF3 -4-n-PrO-phenyl 292 1-cPr-CH (CH2CH2CH3 ) 2-CF3 -4-n-PrO-phenyl 293 l-cPr-CH(CH20CH3) 2-CF3 -4-n-PrO-phenyl 294 1-cPr-CH (CH2CH2OCH3 ) 2-CF3 -4-n-PrO-phenyl 295 (cBu)2CH 2-CF3 -4-n-PrO-phenyl 296 phenyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 297 2-furanyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 298 3-furan(cBu)CH 2-CF3 -4-n-PrO-phenyl 299 2-thienyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 300 3-thienyl(cBu)CH 2-CF3 -4-n-PrO-phenyl 301 2-isoxazolyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 302 2- (5-CH3-furanyl) (cBu)CH 2-CF3 -4-n-PrO-phenyl 303 2-(4-CH3-isoxazolyl) (cBu)CH 2-CF3 -4-n-PrO-phenyl 304 cBu-CH(CH3) 2-CF3 -4-n-PrO-phenyl 305 l-cBu-CH(CH2CH3) 2-CF3 -4-n-PrO-phenyl 306 1-cBu-CH (CH2CH2CH3 ) 2-CF3 -4-n-PrO-phenyl 307 l-cBu-CH(CH20CH3) 2-CF3 -4-n-PrO-phenyl 308 1-cBu-CH (CH2CH2OCH3 ) 2-CF3 -4-n-PrO-phenyl 309 (cPr)2CH 2 , 4-diCF3-phenyl 310 phenyl (cPr)CH 2 , -diCF3-phenyl 311 2-furanyl(cPr)CH 2,4-diCF3-phenyl 312 3-furan(cPr)CH 2 , 4-diCF3-phenyl 313 2-thienyl(cPr)CH 2 , 4-diCF3-phenyl 314 3-thienyl(cPr)CH 2 , 4-diCF3-phenyl 315 2-isoxazolyl (cPr) CH 2 , 4-diCF3-phenyl 316 2- (5-CH3-furanyl) (cPr)CH 2 , 4-diCF3-phenyl 317 2-(4-CH3-isoxazolyl) (cPr)CH 2 , 4-diCF3-phenyl 318 cPr-CH(CH3) 2 , 4-diCF3-phenyl 319 l-cPr-CH(CH2CH3) 2 , 4-diCF3-phenyl 320 1-cPr-CH (CH2CH2CH3 ) 2 , 4-diCF3-phenyl 321 l-cPr-CH(CH20CH3) 2 , 4-diCF3-phenyl 322 1-cPr-CH (CH2CH2OCH3 ) 2 , 4-diCF3-phenyl 323 (cBu)2CH 2 , 4-diCF3-phenyl 324 phenyl (cBu)CH 2 , 4-diCF3-phenyl 325 2-furanyl (cBu)CH 2 , 4-diCF3-phenyl 326 3-furan(cBu)CH 2 , 4-diCF3-phenyl 327 2-thienyl (cBu)CH 2 , 4-diCF3-phenyl 328 3-thienyl (cBu)CH 2 , 4-diCF3-phenyl 329 2-isoxazolyl (cBu) CH 2 , 4-diCF3-phenyl 330 2- (5-CH3-furanyl) (cBu)CH 2 , 4-diCF3-phenyl 331 2-(4-CH3-isoxazolyl) (cBu)CH 2 , 4-diCF3-phenyl 332 cBu-CH(CH3) 2 , 4-diCF3-phenyl 333 l-cBu-CH(CH2CH3) 2 , 4-diCF3-phenyl 334 1-cBu-CH (CH2CH2CH3 ) 2 , 4-diCF3-phenyl 335 l-cBu-CH(CH20CH3) 2 , 4-diCF3-phenyl 336 1-cBu-CH (CH2CH2OCH3 ) 2, 4-diCF3-phenyl 337 (cPr)2CH 2-CF3-4-F-phenyl 338 phenyl (cPr)CH 2-CF3-4-F-phenyl 339 2-furanyl (cPr)CH 2-CF3-4-F-phenyl 340 3-furan(cPr)CH 2-CF3-4-F-phenyl 341 2-thienyl(cPr)CH 2-CF3-4-F-phenyl 342 3-thienyl(cPr)CH 2-CF3-4-F-phenyl 343 2-isoxazolyl (cPr) CH 2-CF3-4-F-phenyl 344 2- (5-CH3-furanyl) (cPr)CH 2-CF3-4-F-phenyl 345 2-(4-CH3-isoxazolyl) (cPr)CH 2-CF3-4-F-phenyl 346 cPr-CH(CH3) 2-CF3-4-F-phenyl 347 l-cPr-CH(CH2CH3) 2 -CF3 -4-F-phenyl 348 1-cPr-CH (CH2CH2CH3 ) 2 -CF3 -4-F-phenyl 349 l-cPr-CH(CH20CH3) 2 -CF3 -4-F-phenyl 350 1-cPr-CH (CH2CH2OCH3 ) 2 -CF3 -4-F-phenyl 351 (cBu)2CH 2 -CF3 -4-F-phenyl 352 phenyl (cBu)CH 2 -CF3 -4-F-phenyl 353 2- furanyl (cBu)CH 2-CF3-4-F-phenyl 354 3-furan(cBu)CH 2 -CF3 -4-F-phenyl 355 2-thienyl(cBu)CH 2-CF3-4-F-phenyl 356 3-thienyl(cBu)CH 2 -CF3 -4-F-phenyl 357 2-isoxazolyl (cBu) CH 2-CF3-4-F-phenyl 358 2- (5-CH3-f uranyl) (cBu)CH 2 -CF3 -4-F-phenyl 359 2-(4-CH3-isoxazolyl) (cBu)CH 2-CF3-4-F-phenyl 360 cBu-CH(CH3) 2 -CF3 -4-F-phenyl 361 l-cBu-CH(CH2CH3) 2 -CF3 -4-F-phenyl 362 1-cBu-CH (CH2CH2CH3 ) 2 -CF3 -4-F-phenyl 363 l-cBu-CH(CH20CH3) 2 -CF3 -4-F-phenyl 364 1-cBu-CH (CH2CH2OCH3 ) 2 -CF3 -4-F-phenyl 365 (cPr)2CH 2-CH3-4-Cl-phenyl 366 phenyl (cPr)CH 2-CH3-4-Cl-phenyl 367 2- furanyl (cPr)CH 2-CH3-4-Cl-phenyl 368 3-furan(cPr)CH 2-CH3-4-Cl-phenyl 369 2-thienyl(cPr)CH 2-CH3-4-Cl-phenyl 370 3-thienyl(cPr)CH 2-CH3-4-Cl-phenyl 371 2-isoxazolyl (cPr) CH 2-CH3-4-Cl-phenyl 372 2- (5-CH3- furanyl) (cPr)CH 2-CH3-4-Cl-phenyl 373 2-(4-CH3-isoxazolyl) (cPr)CH 2-CH3-4-Cl-phenyl 374 cPr-CH(CH3) 2-CH3-4-Cl-phenyl 375 l-cPr-CH(CH2CH3) 2-CH3-4-Cl-phenyl 376 1-cPr-CH (CH2CH2CH3 ) 2-CH3-4-Cl-phenyl 377 l-cPr-CH(CH20CH3) 2-CH3-4-Cl-phenyl 378 1-cPr-CH (CH2CH2OCH3 ) 2-CH3-4-Cl-phenyl 379 (cBu)2CH 2-CH3-4-Cl-phenyl 380 phenyl (cBu)CH 2-CH3-4-Cl-phenyl 381 2- furanyl (cBu)CH 2-CH3-4-Cl-phenyl 382 3-furan(cBu)CH 2-CH3-4-Cl-phenyl 383 2-thienyl(cBu)CH 2-CH3-4-Cl-phenyl 384 3-thienyi (cBu)CH 2-CH3-4-Cl-phenyl 385 2-isoxazolyl (cBu) CH 2-CH3-4-Cl-phenyl 386 2- (5-CH3-1uranyl) (cBu)CH 2-CH3-4-Cl-phenyl 387 2-(4-CH3-isoxazolyl) (cBu)CH 2-CH3-4-Cl-phenyl 388 cBu-CH(CH3) 2-CH3-4-Cl-phenyl 389 l-cBu-CH(CH2CH3) 2-CH3-4-Cl-phenyl 390 l-cBu-CH(CH2CH2CH3) 2-CH3-4-Cl-phenyl 391 l-cBu-CH(CH20CH3) 2-CH3-4-Cl-phenyl 392 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-4-Cl-phenyl 393 (cPr)2CH 2-CH3-4-MeO-phenyl 394 phenyl (cPr)CH 2-CH3-4-MeO-phenyl 395 2-furanyl (cPr)CH 2-CH3-4-MeO-phenyl 396 3-furan(cPr)CH 2-CH3-4-MeO-phenyl 397 2-thienyl(cPr)CH 2-CH3-4-MeO-phenyl 398 3-thienyl(cPr)CH 2-CH3-4-MeO-phenyl 399 2-isoxazolyl (cPr) CH 2-CH3-4-MeO-phenyl 400 2- (5-CH3-furanyl) (cPr)CH 2-CH3-4-MeO-phenyl 401 2-(4-CH3-isoxazolyl) (cPr)CH 2-CH3-4-MeO-phenyl 402 cPr-CH(CH3) 2-CH3-4-MeO-phenyl 403 l-cPr-CH(CH2CH3) 2-CH3-4-MeO-phenyl 404 1-cPr-CH (CH2CH2CH3 ) 2-CH3-4-MeO-phenyl 405 l-cPr-CH(CH20CH3) 2-CH3-4-MeO-phenyl 406 1-cPr-CH (CH2CH2OCH3 ) 2-CH3-4-MeO-phenyl 407 (cBu)2CH 2-CH3-4-MeO-phenyl 408 phenyl (cBu)CH 2-CH3-4-MeO-phenyl 409 2- furanyl (cBu)CH 2-CH3-4-MeO-phenyl 410 3-furan(cBu)CH 2-CH3-4-MeO-phenyl 411 2-thienyl (cBu)CH 2-CH3-4-MeO-phenyl 412 3-thienyl (cBu)CH 2-CH3-4-MeO-phenyl 413 2-isoxazolyl (cBu) CH 2-CH3-4-MeO-phenyl 414 2- (5-CH3-furanyl) (cBu)CH 2-CH3-4-MeO-phenyl 415 2-(4-CH3-isoxazolyl) (cBu)CH 2-CH3-4-MeO-phenyl 416 cBu-CH(CH3) 2-CH3-4-MeO-phenyl 417 l-cBu-CH(CH2CH3) 2-CH3-4-MeO-phenyl 418 1-cBu-CH (CH2CH2CH3 ) 2-CH 3 -4-MeO-phenyl 419 l-cBu-CH(CH20CH3) 2-CH3-4-MeO-phenyl 420 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-4-MeO-phenyl 421 (cPr)2CH 2, 4-diCH3-phenyl 422 phenyl (cPr)CH 2,4-diCH3-phenyl 423 2-furanyl (cPr)CH 2, 4-diCH3-phenyl 424 3-furan(cPr)CH 2, 4-diCH3-phenyl 425 2-thienyl(cPr)CH 2, 4-diCH3-phenyl 426 3-thienyl(cPr)CH 2, 4-diCH3-phenyl 427 2-isoxazolyl (cPr)CH 2, 4-diCH3-phenyl 428 2- (5-CH3-furanyl) (cPr)CH 2, 4-diCH3-phenyl 429 2-(4-CH3-isoxazolyl) (cPr)CH 2, 4-diCH3-phenyl 430 cPr-CH(CH3) 2, 4-diCH3-phenyl 431 l-cPr-CH(CH2CH3) 2, 4-diCH3-phenyl 432 1-cPr-CH (CH2CH2CH3 ) 2, 4-diCH3-phenyl 433 l-cPr-CH(CH20CH3) 2, 4-diCH3-phenyl 434 1-cPr-CH (CH2CH2OCH3 ) 2, 4-diCH3-phenyl 435 (cBu)2CH 2, 4-diCH3-phenyl 436 phenyl (cBu)CH 2, 4-diCH3-phenyl 437 2-furanyl (cBu)CH 2, 4-diCH3-phenyl 438 3-furan(cBu)CH 2, 4-diCH3-phenyl 439 2-thienyl(cBu)CH 2, 4-diCH3-phenyl 440 3-thienyl(cBu)CH 2, 4-diCH3-phenyl 441 2-isoxazolyl (cBu)CH 2, 4-diCH3-phenyl 442 2- (5-CH3-furanyl) (cBu)CH 2, 4-diCH3-phenyl 443 2-(4-CH3-isoxazolyl) (cBu)CH 2, 4-diCH3-phenyl 444 cBu-CH(CH3) 2, 4-diCH3-phenyl 445 l-cBu-CH(CH2CH3) 2, 4-diCH3-phenyl 446 1-cBu-CH (CH2CH2CH3 ) 2, 4-diCH3-phenyl 447 l-cBu-CH(CH20CH3) 2, 4-diCH3-phenyl 448 1-cBu-CH (CH2CH2OCH3 ) 2, 4-diCH3-phenyl 449 (cPr)2CH 2-CH3-4- (CH3 ) 2N-phenyl 450 phenyl (cPr)CH 2-CH3-4- (CH3) 2N- henyl 451 2-furanyl (cPr)CH 2-CH3-4- (CH3 ) 2N-phenyl 452 3-furan(cPr)CH 2-CH3-4- (CH3 ) 2N-phenyl 453 2-thienyl(cPr)CH 2- ■ CH3-4- (CH3 ) 2N-phenyl 454 3-thienyl(cPr)CH 2-CH3-4- (CH3 ) 2N-phenyl 455 2-isoxazolyl (cPr) CH 2- ■ CH3-4- (CH3) 2N-phenyl 456 2- (5-CH3-furanyl) (cPr)CH 2- ■ CH3-4- (CH3 ) 2N-phenyl 457 2-(4-CH3-isoxazolyl) (cPr)CH 2- ■ CH3-4- (CH3 ) 2N-phenyl 458 cPr-CH(CH3) 2- ■ CH3-4- (CH3 ) 2N-phenyl 459 l-cPr-CH(CH2CH3) 2-CH3-4- (CH3 ) 2N-phenyl 460 1-cPr-CH (CH2CH2CH3 ) 2- ■ CH3-4- (CH3 ) 2N-phenyl 461 l-cPr-CH(CH20CH3) 2-CH3-4-(CH3)2N-phenyl 462 1-cPr-CH (CH2CH2OCH3 ) 2-CH3-4- (CH3 ) 2N- phenyl 463 (cBu)2CH 2-CH3-4-(CH3)2N-phenyl 464 phenyl (cBu)CH 2-CH3-4-(CH3)2N-phenyl 465 2- furanyl (cBu)CH 2-CH3-4-(CH3)2N-phenyl 466 3-furan(cBu)CH 2-CH3-4- (CH3)2N- phenyl 467 2-thienyl(cBu)CH 2-CH3-4-(CH3)2N-phenyl 468 3-thienyl(cBu)CH 2-CH3-4- (CH3 ) 2N- phenyl 469 2-isoxazolyl (cBu) CH 2-CH3-4- (CH3 ) 2N-phenyl 470 2- (5-CH3- furanyl) (cBu)CH 2-CH3-4- (CH3 ) 2N-phenyl 471 2- (4-CH3-isoxazolyl) (cBu)CH 2-CH3-4-(CH3)2N-phenyl 472 cBu-CH(CH3) 2-CH3-4-(CH3)2N-phenyl 473 l-cBu-CH(CH2CH3) 2-CH3-4-(CH3)2N-phenyl 474 1-cBu-CH (CH2CH2CH3 ) 2-CH3-4-(CH3)2N-phenyl 475 l-cBu-CH(CH20CH3) 2-CH3-4- (CH3 ) 2N-phenyl 476 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-4- (CH3) 2 N- phenyl 477 (cPr)2CH 2 -MeO-4-CH3 -phenyl 478 phenyl (cPr)CH 2-MeO-4-CH3-phenyl 479 2- f uranyl (cPr)CH 2-MeO-4-CH3-phenyl 480 3-furan(cPr)CH 2-MeO-4-CH3-phenyl 481 2-thienyl(cPr)CH 2 -MeO-4 -CH3 -phenyl 482 3-thienyl(cPr)CH 2 -MeO-4-CH3 -phenyl 483 2-isoxazolyl (cPr) CH 2 -MeO-4-CH3 -phenyl 484 2- (5-CH3- furanyl) (cPr)CH 2 -MeO-4 -CH3 -phenyl 485 2-(4-CH3-isoxazolyl) (cPr)CH 2-MeO-4-CH " 3-phenyl 486 cPr-CH(CH3) 2-MeO-4-CH3-phenyl 487 l-cPr-CH(CH2CH3) 2 -MeO-4-CH3 -phenyl 488 l-cPr-CH(CH2CH2CH3) 2-MeO-4-CH3-phenyl 489 l-cPr-CH(CH20CH3) 2-MeO-4-CH3-phenyl 490 1-cPr-CH (CH2CH2OCH3 ) 2-MeO-4-CH3-phenyl 491 (cBu)2CH 2 -MeO-4 -CH3 -phenyl 492 phenyl (cBu)CH 2-MeO-4-CH3-phenyl 493 2- furanyl (cBu)CH 2 -MeO-4 -CH3 -phenyl 494 3-furan(cBu)CH 2 -MeO-4 -CH3 -phenyl 495 2 - thienyl (cBu)CH 2 -MeO-4 -CH3 -phenyl 496 3-thienyl(cBu)CH 2 -MeO-4 -CH3 -phenyl 497 2-isoxazolyl (cBu)CH 2-MeO-4-CH3-phenyl 498 2- (5-CH3- furanyl) (cBu)CH 2 -MeO-4-CH3 -phenyl 499 2-(4-CH3-isoxazolyl) (cBu)CH 2-MeO-4-CH3-phenyl 500 cBu-CH(CH3) 2-MeO-4-CH3-phenyl 501 l-cBu-CH(CH2CH3) 2-MeO-4-CH3-phenyl 502 l-cBu-CH(CH2CH2CH3) 2-MeO-4-CH3-phenyl 503 l-cBu-CH(CH20CH3) 2-MeO-4-CH " 3-phenyl 504 1-cBu-CH (CH2CH2OCH3 ) 2-MeO-4-CH3-phenyl 505 (cPr)2CH 2-MeO-4-CF3-phenyl 506 phenyl (cPr)CH 2-MeO-4-CF3-phenyl 507 2-furanyl (cPr)CH 2-MeO-4-CF3-phenyl 508 3-furan(cPr)CH 2-MeO-4-CF3-phenyl 509 2-thienyl(cPr)CH 2-MeO-4-CF3-phenyl 510 3-thienyl(cPr)CH 2-MeO-4-CF3-phenyl 511 2-isoxazolyl (cPr) CH 2-MeO-4-CF3-phenyl 512 2- (5-CH3-furanyl) (cPr)CH 2-MeO-4-CF3-phenyl 513 2-(4-CH3-isoxazolyl) (cPr)CH 2-MeO-4-CF3-phenyl 514 cPr-CH(CH3) 2-MeO-4-CF3-phenyl 515 l-cPr-CH(CH2CH3) 2-MeO-4-CF3-phenyl 516 1-cPr-CH (CH2CH2CH3 ) 2-MeO-4-CF3-phenyl 517 l-cPr-CH(CH20CH3) 2-MeO-4-CF3-phenyl 518 1-cPr-CH (CH2CH2OCH3 ) 2-MeO-4-CF3-phenyl 519 (cBu)2CH 2-MeO-4-CF3-phenyl 520 phenyl (cBu)CH 2-MeO-4-CF3-phenyl 521 2-furanyl (cBu)CH 2-MeO-4-CF3-phenyl 522 3-furan(cBu)CH 2-MeO-4-CF3-phenyl 523 2-thienyl(cBu)CH 2-MeO-4-CF3-phenyl 524 3-thienyl(cBu)CH 2-MeO-4-CF3-phenyl 525 2-isoxazolyl (cBu) CH 2-MeO-4-CF3-phenyl 526 2- (5-CH3-furanyl) (cBu)CH 2-MeO-4-CF3-phenyl 527 2-(4-CH3-isoxazolyl) (cBu)CH 2-MeO-4-CF3-phenyl 528 cBu-CH(CH3) 2-MeO-4-CF3-phenyl 529 l-cBu-CH(CH2CH3) 2-MeO-4-CF3-phenyl 530 1-cBu-CH (CH2CH2CH3 ) 2-MeO-4-CF3-phenyl 531 l-cBu-CH(CH20CH3) 2-MeO-4-CF3-phenyl 532 1-cBu-CH (CH2CH2OCH3 ) 2-MeO-4-CF3-phenyl 533 (cPr)2CH 2-MeO-4-Cl-phenyl 534 phenyl (cPr)CH 2-MeO-4-Cl-phenyl 535 2-furanyl(cPr)CH 2-MeO-4-Cl-phenyl 536 3-furan(cPr)CH 2-MeO-4-Cl-phenyl 537 2-thienyl(cPr)CH 2-MeO-4-Cl-phenyl 538 3-thienyl(cPr)CH 2-MeO-4-Cl-phenyl 539 2-isoxazolyl (cPr) CH 2-MeO-4-Cl-phenyl 540 2- (5-CH3-furanyl) (cPr)CH 2-MeO-4-Cl-phenyl 541 2-(4-CH3-isoxazolyl) (cPr)CH 2-MeO-4-Cl-phenyl 542 cPr-CH(CH3) 2-MeO-4-Cl-phenyl 543 l-cPr-CH(CH2CH3) 2-MeO-4-Cl-phenyl 544 l-cPr-CH(CH2CH2CH3) 2-MeO-4-Cl-phenyl 545 l-cPr-CH(CH20CH3) 2-MeO-4-Cl-phenyl 546 1-cPr-CH (CH2CH2OCH3 ) 2-MeO-4-Cl-phenyl 547 (cBu)2CH 2-MeO-4-Cl-phenyl 548 phenyl (cBu)CH 2-MeO-4-Cl-phenyl 549 2- furanyl (cBu)CH 2-MeO-4-Cl-phenyl 550 3-furan(cBu)CH 2-MeO-4-Cl-phenyl 551 2-thienyl(cBu)CH 2-MeO-4-Cl-phenyl 552 3-thienyl(cBu)CH 2-MeO-4-Cl-phenyl 553 2-isoxazolyl (cBu) CH 2-MeO-4-Cl-phenyl 554 2- (5-CH3-furanyl) (cBu)CH 2-MeO-4-Cl-phenyl 555 2-(4-CH3-isoxazolyl) (cBu)CH 2-MeO-4-Cl-phenyl 556 cBu-CH(CH3) 2-MeO-4-Cl-phenyl 557 l-cBu-CH(CH2CH3) 2-MeO-4-Cl-phenyl 558 l-cBu-CH(CH2CH2CH3) 2-MeO-4-Cl-phenyl 559 l-cBu-CH(CH20CH3) 2-MeO-4-Cl-phenyl 560 1-cBu-CH (CH2CH2OCH3 ) 2-MeO-4-Cl-phenyl 561 (cPr)2CH 2 , 4-diMeO-phenyl 562 phenyl (cPr)CH 2 , 4-diMeO-phenyl 563 2-furanyl(cPr)CH 2 , 4-diMeO-phenyl 564 3-furan(cPr)CH 2 , 4-diMeO-phenyl 565 2-thienyl(cPr)CH 2 , 4-diMeO-phenyl 566 3-thienyl(cPr)CH 2 , 4-diMeO-phenyl 567 2-isoxazolyl (cPr) CH 2 , 4-diMeO-phenyl 568 2- (5-CH3-furanyl) (cPr)CH 2 , 4-diMeO-phenyl 569 2-(4-CH3-isoxazolyl) (cPr)CH 2 , 4-diMeO-phenyl 570 cPr-CH(CH3) 2 , 4-diMeO-phenyl 571 l-cPr-CH(CH2CH3) 2 , 4-diMeO-phenyl 572 1-cPr-CH (CH2CH2CH3 ) 2 , 4-diMeO-phenyl 573 l-cPr-CH(CH20CH3) 2 , 4-diMeO-phenyl 574 1-cPr-CH (CH2CH2OCH3 ) 2 , 4-diMeO-phenyl 575 (cBu)2CH 2, 4-diMeO-phenyl 576 phenyl (cBu)CH 2, 4-diMeO-phenyl 577 2- furanyl (cBu)CH 2, 4-diMeO-phenyl 578 3-furan(cBu)CH 2, 4-diMeO-phenyl 579 2-thienyl(cBu)CH 2, 4-diMeO-phenyl 580 3-thienyl(cBu)CH 2, 4-diMeO-phenyl 581 2-isoxazolyl (cBu) CH 2, 4-diMeO-phenyl 582 2- (5-CH3-furanyl) (cBu)CH 2, 4-diMeO-phenyl 583 2- (4-CH3-isoxazolyl) (cBu)CH 2, 4-diMeO- henyl 584 cBu-CH(CH3) 2, 4-diMeO-phenyl 585 l-cBu-CH(CH2CH3) 2, 4-diMeO-phenyl 586 1-cBu-CH (CH2CH2CH3 ) 2, 4-diMeO-phenyl 587 l-cBu-CH(CH20CH3) 2, 4-diMeO-phenyl 588 1-cBu-CH (CH2CH2OCH3 ) 2, 4-diMeO-phenyl 589 (cPr)2CH 2, 4-diCl-6-CH3-phenyl 590 phenyl (cPr)CH 2, 4-diCl-6-CH3-phenyl 591 2-furanyl(cPr)CH 2, 4-diCl-6-CH3-phenyl 592 3-furan(cPr)CH 2, 4-diCl-6-CH3-phenyl 593 2-thienyl(cPr)CH 2, 4-diCl-6-CH3-phenyl 594 3-thienyl(cPr)CH 2, 4-diCl-6-CH3-phenyl 595 2-isoxazolyl (cPr) CH 2, 4-diCl-6-CH3-phenyl 596 2- (5-CH3-furanyl) (cPr)CH 2, 4-diCl-6-CH3-phenyl 597 2-(4-CH3-isoxazolyl) (cPr)CH 2, 4-diCl-6-CH3-phenyl 598 cPr-CH(CH3) 2, 4-diCl-6-CH3-phenyl 599 l-cPr-CH(CH2CH3) 2, 4-diCl-6-CH3-phenyl 600 1-cPr-CH (CH2CH2CH3 ) 2, 4-diCl-6-CH3-phenyl 601 l-cPr-CH(CH20CH3) 2, 4-diCl-6-CH3-phenyl 602 1-cPr-CH (CH2CH2OCH3 ) 2, 4-diCl-6-CH3-phenyl 603 (cBu)2CH 2, 4-diCl-6-CH3-phenyl 604 phenyl (cBu)CH 2, 4-diCl-6-CH3-phenyl 605 2-furanyl (cBu)CH 2, 4-diCl-6-CH3-phenyl 606 3-furan(cBu)CH 2, 4-diCl-6-CH3-phenyl 607 2-thienyl(cBu)CH 2, 4-diCl-6-CH3-phenyl 608 3-thienyl(cBu)CH 2, 4-diCl-6-CH3-phenyl 609 2-isoxazolyl (cBu)CH 2, 4-diCl-6-CH3-phenyl 610 2- (5-CH3-furanyl) (cBu)CH 2, 4-diCl-6-CH3-phenyl 611 2-(4-CH3-isoxazolyl) (cBu)CH 2, 4-diCl-6-CH3-phenyl 612 cBu-CH(CH3) 2, 4-diCl-6-CH3-phenyl 613 l-cBu-CH(CH2CH3) 2, 4-diCl-6-CH3 -phenyl 614 l-cBu-CH(CH2CH2CH3) 2, 4-diCl- 6 -CH3 -phenyl 615 l-cBu-CH(CH20CH3) 2, 4-diCl- 6 -CH3 -phenyl 616 1-cBu-CH (CH2CH2OCH3 ) 2, 4-diCl-6-CH3-phenyl 617 (cPr)2CH 2, 4-diCl-5-F-phenyl 618 phenyl (cPr)CH 2, 4-diCl-5 -F-phenyl 619 2-furanyl(cPr)CH 2, 4-diCl- 5 -F-phenyl 620 3-furan(cPr)CH 2, 4-diCl- 5 -F-phenyl 621 2-thienyl(cPr)CH 2, 4-diCl- 5 -F-phenyl 622 3-thienyl(cPr)CH 2 4 -diCl- 5 -F-phenyl 623 2-isoxazolyl (cPr) CH 2 4-diCl- 5 -F-phenyl 624 2- (5-CH3- furanyl) (cPr)CH 2 4-diCl-5 -F-phenyl 625 2-(4-CH3-isoxazolyl) (cPr)CH 2 4-diCl-5 -F-phenyl 626 cPr-CH(CH3) 2 4-diCl- 5 -F-phenyl 627 l-cPr-CH(CH2CH3) 2 4-diCl- 5 -F-phenyl 628 1-cPr-CH (CH2CH2CH3 ) 2 4-diCl-5 -F-phenyl 629 l-cPr-CH(CH20CH3) 2 4-diCl-5 -F-phenyl 630 1-cPr-CH (CH2CH2OCH3 ) 2 4-diCl-5 -F-phenyl 631 (cBu)2CH 2 4-diCl-5 -F-phenyl 632 phenyl (cBu)CH 2 4-diCl- 5 -F-phenyl 633 2- furanyl (cBu)CH 2 4-diCl- 5 -F-phenyl 634 3-furan(cBu)CH 2 4-diCl- 5 -F-phenyl 635 2 - thienyl ( cBu) CH 2 4-diCl- 5 -F-phenyl 636 3-thienyl(cBu)CH 2 4-diCl-5 -F-phenyl 637 2 - isoxazolyl ( cBu) CH 2 4-diCl- 5 -F-phenyl 638 2- (5-CH3- furanyl) (cBu)CH 2 4-diCl-5-F-phenyl 639 2-(4-CH3-isoxazolyl) (cBu)CH 2 4-diCl-5-F-phenyl 640 cBu-CH(CH3) 2 4-diCl-5 -F-phenyl 641 l-cBu-CH(CH2CH3) 2 4-diCl- 5 -F-phenyl 642 1-cBu-CH (CH2CH2CH3 ) 2 , 4-diCl-5-F-phenyl 643 l-cBu-CH(CH20CH3) 2 , 4-diCl- 5 -F-phenyl 644 1-cBu-CH (CH2CH2OCH3 ) 2 ,4-diCl-5-F-phenyl 645 (cPr)2CH 2 , 4-diCl-6-MeS-phenyl 646 phenyl (cPr)CH 2 , 4-diCl-6-MeS-phenyl 647 2- f uranyl (cPr)CH 2 , 4-diCl-6-MeS-phenyl 648 3-furan(cPr)CH 2 , 4-diCl-6-MeS-phenyl 649 2-thienyl(cPr)CH 2 , 4-diCl-6-MeS-phenyl 650 3-thienyl(cPr)CH 2 , 4-diCl-6-MeS-phenyl 651 2-isoxazolyl (cPr) CH 2, 4-diCl-6-MeS-phenyl 652 2- (5-CH3- furanyl) (cPr)CH 2, 4-diCl-6-MeS-phenyl 653 2-(4-CH3-isoxazolyl) (cPr)CH 2 4-diCl-6-MeS-phenyl 654 cPr-CH(CH3) 2 4-diCl-6-MeS-phenyl 655 l-cPr-CH(CH2CH3) 2 4-diCl-6-MeS-phenyl 656 l-cPr-CH(CH2CH2CH3) 2 4-diCl-6-MeS-phenyl 657 l-cPr-CH(CH20CH3) 2 4-diCl-6-MeS-phenyl 658 1-cPr-CH (CH2CH2OCH3 ) 2 4-diCl-6-MeS-phenyl 659 (cBu)2CH 2 4-diCl-6-MeS-phenyl 660 phenyl (cBu)CH 2 4-diCl-6-MeS-phenyl 661 2-furanyl(cBu)CH 2 4-diCl-6-MeS-phenyl 662 3-furan(cBu)CH 2 4-diCl-6-MeS-phenyl 663 2-thienyl(cBu)CH 2 4-diCl-6-MeS-phenyl 664 3-thienyl(cBu)CH 2 4-diCl-6-MeS-phenyl 665 2-isoxazolyl (cBu) CH 2 4-diCl-6-MeS-phenyl 666 2- (5-CH3- furanyl) (cBu)CH 2 4-diCl-6-MeS-phenyl 667 2-(4-CH3-isoxazolyl) (cBu)CH 2 4-diCl-6-MeS-phenyl 668 cBu-CH(CH3) 2 4-diCl-6-MeS-phenyl 669 l-cBu-CH(CH2CH3) 2 4-diCl-6-MeS-phenyl 670 1-cBu-CH (CH2CH2CH3 ) 2 4-diCl-6-MeS-phenyl 671 l-cBu-CH(CH20CH3) 2 4-diCl-6-MeS-phenyl 672 1-cBu-CH (CH2CH2OCH3 ) 2 4-diCl-6-MeS-phenyl 673 (cPr)2CH 2 4-diCl-6-MeO-phenyl 674 phenyl (cPr)CH 2 4-diCl-6-MeO-phenyl 675 2- f uranyl (cPr)CH 2 4-diCl-6-MeO-phenyl 676 3-furan(cPr)CH 2 4-diCl-6-MeO-phenyl 677 2-thienyl(cPr)CH 2 4-diCl-6-MeO-phenyl 678 3-thienyl(cPr)CH 2 4-diCl-6-MeO-phenyl 679 2-isoxazolyl (cPr)CH 2 4-diCl-6-MeO-phenyl 680 2- (5-CH3- furanyl) (cPr)CH 2 4-diCl-6-MeO-phenyl 681 2-(4-CH3-isoxazolyl) (cPr)CH 2 4-diCl-6-MeO-phenyl 682 cPr-CH(CH3) 2 4-diCl-6-MeO-phenyl 683 l-cPr-CH(CH2CH3) 2 4-diCl-6-MeO-phenyl 684 l-cPr-CH(CH2CH2CH3) 2 4-diCl-6-MeO-phenyl 685 l-cPr-CH(CH20CH3) 2 4-diCl- 6 -MeO- phenyl 686 1-cPr-CH (CH2CH2OCH3 ) 2 4-diCl-6-MeO-phenyl 687 (cBu)2CH 2 4-diCl-6-MeO-phenyl 688 phenyl (cBu)CH 2 4-diCl-6-MeO-phenyl 689 2- furanyl (cBu)CH 2, 4-diCl-6-MeO-phenyl 690 3-furan(cBu)CH 2, 4-diCl-6-MeO-phenyl 691 2-thienyl(cBu)CH 2, 4-diCl-6-MeO-phenyl 692 3-thienyl(cBu)CH 2, 4-diCl-6-MeO-phenyl 693 2-isoxazolyl (cBu) CH 2, 4-diCl-6-MeO-phenyl 694 2- (5-CH3- furanyl) (cBu)CH 2, 4-diCl-6-MeO-phenyl 695 2-(4-CH3-isoxazolyl) (cBu)CH 2, 4-diCl-6-MeO-phenyl 696 cBu-CH(CH3) 2, 4-diCl-6-MeO-phenyl 697 l-cBu-CH(CH2CH3) 2 4-diCl-6-MeO-phenyl 698 1-cBu-CH (CH2CH2CH3 ) 2 4-diCl-6-MeO-phenyl 699 l-cBu-CH(CH20CH3) 2 4-diCl-6-MeO-phenyl 700 1-cBu-CH (CH2CH2OCH3 ) 2 4-diCl-6-MeO-phenyl 701 (cPr)2CH 2 5-diCl-4-MeO-phenyl 702 phenyl (cPr)CH 2 5-diCl-4-MeO-phenyl 703 2- f uranyl (cPr)CH 2 5-diCl-4-MeO-phenyl 704 3-furan(cPr)CH 2 5-diCl-4-MeO-phenyl 705 2-thienyl(cPr)CH 2 5-diCl-4-MeO-phenyl 706 3-thienyl(cPr)CH 2 5-diCl-4-MeO-phenyl 707 2-isoxazolyl (cPr) CH 2 5-diCl-4-MeO-phenyl 708 2- (5-CH3-f uranyl) (cPr)CH 2 5-diCl-4-MeO-phenyl 709 2-(4-CH3-isoxazolyl) (cPr)CH 2 5-diCl-4-MeO-phenyl 710 cPr-CH(CH3) 2 5-diCl-4-MeO-phenyl 711 l-cPr-CH(CH2CH3) 2 5-diCl-4-MeO-phenyl 712 l-cPr-CH(CH2CH2CH3) 2 5-diCl-4-MeO-phenyl 713 l-cPr-CH(CH20CH3) 2 5-diCl-4-MeO-phenyl 714 1-cPr-CH (CH2CH2OCH3 ) 2 5-diCl-4-MeO-phenyl 715 (cBu)2CH 2 5-diCl-4-MeO-phenyl 716 phenyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 717 2- furanyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 718 3-furan(cBu)CH 2 , 5-diCl-4-MeO-phenyl 719 2 - thienyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 720 3 - thienyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 721 2-isoxazolyl (cBu) CH 2 , 5-diCl-4-MeO-phenyl 722 2- (5-CH3- furanyl) (cBu)CH 2 , 5-diCl-4-MeO-phenyl 723 2-(4-CH3-isoxazolyl) (cBu)CH 2 , 5-diCl-4-MeO-phenyl 724 cBu-CH(CH3) 2 , 5-diCl-4-MeO-phenyl 725 l-cBu-CH(CH2CH3) 2 , 5-diCl-4-MeO-phenyl 726 l-cBu-CH(CH2CH2CH3) 2 , 5-diCl-4-MeO-phenyl 727 l-cBu-CH(CH20CH3) 2 , 5-diCl-4-Me0-phenyl 728 l-cBu-CH(CH2CH20CH3) 2 , 5-diCl-4-MeO-phenyl 729 (cPr)2CH 2,4, 6-triCl-phenyl 730 phenyl (cPr)CH 2,4, 6-triCl-phenyl 731 2-furanyl (cPr)CH 2,4, 6-triCl-phenyl 732 3-furan(cPr)CH 2,4, 6-triCl-phenyl 733 2-thienyl(cPr)CH 2,4, 6-triCl-phenyl 734 3-thienyl(cPr)CH 2,4, 6-triCl-phenyl 735 2-isoxazolyl (cPr)CH 2,4, 6-triCl-phenyl 736 2- (5-CH3-furanyl) (cPr)CH 2,4, 6-triCl-phenyl 737 2-(4-CH3-isoxazolyl) (cPr)CH 2,4, 6-triCl-phenyl 738 cPr-CH(CH3) 2,4, 6-triCl-phenyl 739 l-cPr-CH(CH2CH3) 2,4, 6-triCl-phenyl 740 l-cPr-CH(CH2CH2CH3) 2,4, 6-triCl-phenyl 741 l-cPr-CH(CH20CH3) 2,4, 6-triCl-phenyl 742 l-cPr-CH(CH2CH20CH3) 2,4, 6-triCl-phenyl 743 (cBu)2CH 2,4, 6-triCl-phenyl 744 phenyl (cBu)CH 2,4, 6-triCl-phenyl 745 2-furanyl (cBu)CH 2,4, 6-triCl-phenyl 746 3-furan(cBu)CH 2,4, 6-triCl-phenyl 747 2-thienyl(cBu)CH 2,4, 6-triCl-phenyl 748 3-thienyl(cBu)CH 2,4, 6-triCl-phenyl 749 2-isoxazolyl (cBu)CH 2,4, 6-triCl-phenyl 750 2- (5-CH3-1uranyl) (cBu)CH 2,4, 6-triCl-phenyl 751 2-(4-CH3-isoxazolyl) (cBu)CH 2,4, 6-triCl-phenyl 752 cBu-CH(CH3) 2,4, 6-triCl-phenyl 753 l-cBu-CH(CH2CH3) 2,4, 6-triCl-phenyl 754 l-cBu-CH(CH2CH2CH3) 2,4, 6-triCl-phenyl 755 l-cBu-CH(CH20CH3) 2,4, 6-triCl-phenyl 756 l-cBu-CH(CH2CH20CH3) 2,4, 6-triCl-phenyl 757 (cPr)2CH 2-Cl-4-CH3-5-F-phenyl 758 phenyl (cPr)CH 2-Cl-4-CH3-5-F-phenyl 759 2-furanyl(cPr)CH 2-Cl-4-CH3-5-F-phenyl 760 3-furan(cPr)CH 2-Cl-4-CH3-5-F-phenyl 761 2-thienyl(cPr)CH 2-Cl-4-CH3-5-F-phenyl 762 3-thienyl(cPr)CH 2-Cl-4-CH3-5-F-phenyl 763 2-isoxazolyl (cPr)CH 2-Cl-4-CH3-5-F-phenyl 764 2- (5-CH3-furanyl) (cPr)CH 2-Cl-4-CH3-5-F-phenyl 765 2-(4-CH3-isoxazolyl) (cPr)CH 2-Cl-4-CH3-5-F-phenyl 766 cPr-CH(CH3) 2-Cl-4-CH3-5-F-phenyl 767 l-cPr-CH(CH2CH3) 2-Cl-4-CH3-5-F-phenyl 768 l-cPr-CH(CH2CH2CH3) 2-Cl-4-CH3-5-F-phenyl 769 l-cPr-CH(CH20CH3) 2-Cl-4-CH3-5-F-phenyl 770 1-cPr-CH (CH2CH2OCH3 ) 2-Cl-4-CH3-5-F-phenyl 771 (cBu)2CH 2-Cl-4-CH3-5-F-phenyl 772 phenyl (cBu)CH 2-Cl-4-CH3-5-F-phenyl 773 2- furanyl (cBu)CH 2-Cl-4-CH3-5-F-phenyl 774 3-furan(cBu)CH 2-Cl-4-CH3-5-F-phenyl 775 2-thienyl(cBu)CH 2-Cl-4-CH3-5-F-phenyl 776 3-thienyl(cBu)CH 2-Cl-4-CH3-5-F-phenyl 777 2-isoxazolyl (cBu) CH 2-Cl-4-CH3-5-F-phenyl 778 2- (5-CH3- furanyl) (cBu)CH 2-Cl-4-CH3-5-F-phenyl 779 2-(4-CH3-isoxazolyl) (cBu)CH 2-Cl-4-CH3-5-F-phenyl 780 cBu-CH(CH3) 2-Cl-4-CH3-5-F-phenyl 781 l-cBu-CH(CH2CH3) 2-Cl-4-CH3-5-F-phenyl 782 1-cBu-CH (CH2CH2CH3 ) 2-Cl-4-CH3-5-F-phenyl 783 l-cBu-CH(CH20CH3) 2-Cl-4-CH3-5-F-phenyl 784 1-cBu-CH (CH2CH2OCH3 ) 2-Cl-4-CH3-5-F-phenyl 785 (cPr)2CH 2-Cl-4-MeO-5-CH3-phenyl 786 phenyl (cPr)CH 2 -Cl-4-MeO-5-CH3 -phenyl 787 2- furanyl (cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 788 3-furan(cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 789 2-thienyl(cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 790 3-thienyl(cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 791 2-isoxazolyl (cPr)CH 2 -Cl-4-MeO-5-CH3 -phenyl 792 2- (5-CH3- furanyl) (cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 793 2- (4-CH3-isoxazolyl) (cPr)CH 2-Cl-4-MeO-5-CH3-phenyl 794 cPr-CH(CH3) 2-Cl-4-MeO-5-CH3-phenyl 795 l-cPr-CH(CH2CH3) 2-Cl-4-MeO-5-CH3-phenyl 796 1-cPr-CH (CH2CH2CH3 ) 2-Cl-4-MeO-5-CH3-phenyl 797 l-cPr-CH(CH20CH3) 2-Cl-4-MeO-5-CH3-phenyl 798 1-cPr-CH (CH2CH2OCH3 ) 2-Cl-4-MeO-5-CH3-phenyl 799 (cBu)2CH 2-Cl-4-MeO-5-CH3-phenyl 800 phenyl (cBu)CH 2-Cl-4-MeO-5-CH3-phenyl 801 2- furanyl (cBu)CH 2-Cl-4-MeO-5-CH3-phenyl 802 3-furan(cBu)CH 2-Cl-4-MeO-5-CH3-phenyl 803 2-thienyl(cBu)CH 2-C1 4-MeO-5 CH3-phenyl 804 3-thienyl(cBu)CH 2-C1 4-MeO-5 CH3-phenyl 805 2-isoxazolyl (cBu)CH 2-C1 4-MeO-5 CH3-phenyl 806 2- (5-CH3-furanyl) (cBu) CH 2-C1 4-MeO-5 CH3-phenyl 807 2-(4-CH3-isoxazolyl) (cBu ) CH 2-C1-4-MeO-5-CH3-phenyl 808 cBu-CH(CH3) 2-C1-4-MeO-5-•CH3-phenyl 809 l-cBu-CH(CH2CH3) 2-C1-•4-MeO-5-•CH3-phenyl 810 l-cBu-CH(CH2CH2CH3) 2-C1- ■ 4-MeO-5--CH3-phenyl 811 l-cBu-CH(CH20CH3) 2-C1- ■ 4-MeO-5--CH3-phenyl 812 l-cBu-CH(CH2CH20CH3) 2-C1-•4-MeO-5--CH3-phenyl 813 (cPr)2CH 2-C1--4-MeO-5--F-phenyl 814 phenyl (cPr)CH 2-C1--4-MeO-5--F-phenyl 815 2- furanyl (cPr)CH 2-C1--4-MeO-5--F-phenyl 816 3-furan(cPr)CH 2-C1--4-MeO-5--F-phenyl 817 2-thienyl(cPr)CH 2-C1--4-MeO-5--F-phenyl 818 3-thienyl(cPr)CH 2-C1--4-MeO-5--F-phenyl 819 2-isoxazolyl (cPr)CH 2-C1--4-MeO-5--F-phenyl 820 2- (5-CH3-furanyl ) (cPr)CH 2-C1--4-MeO-5--F-phenyl 821 2-(4-CH3-isoxazolyl) (cPr)CH 2-C1--4-MeO-5--F-phenyl 822 cPr-CH(CH3) 2-C1--4-MeO-5--F-phenyl 823 l-cPr-CH(CH2CH3) 2-C1--4-MeO-5--F-phenyl 824 l-cPr-CH(CH2CH2CH3) 2-C1--4-MeO-5--F-phenyl 825 l-cPr-CH(CH20CH3) 2-Cl--4-MeO-5--F-phenyl 826 l-cPr-CH(CH2CH20CH3) 2-C1--4-MeO-5--F-phenyl 827 (cBu)2CH 2-C1--4-MeO-5--F-phenyl 828 phenyl (cBu)CH 2-C1--4-MeO-5--F-phenyl 829 2-furanyl (cBu)CH 2-C1--4-MeO-5--F-phenyl 830 3-furan(cBu)CH 2-C -4-MeO-5-F-phenyl 831 2-thienyl(cBu)CH 2-C1-4-MeO-5-F-phenyl 832 3-thienyl(cBu)CH 2-C1-4-MeO-5-F-phenyl 833 2-isoxazolyl (cBu)CH 2-C1-4-MeO-5-F-phenyl 834 2- (5-CH3-1uranyl ) (cBu)CH 2-C1-4-MeO-5-F-phenyl 835 2-(4-CH3-isoxazolyl) (cBu)CH 2-C1-4-MeO-5-F-phenyl 836 cBu-CH(CH3) 2-C1-4-MeO-5-F-phenyl 837 l-cBu-CH(CH2CH3) 2-C1-4-MeO-5-F-phenyl 838 l-cBu-CH(CH2CH2CH3) 2-C1-4-MeO-5-F-phenyl 839 l-cBu-CH(CH20CH3) 2-C1-4-MeO-5-F-phenyl 840 l-cBu-CH(CH2CH20CH3) 2-C1 4-MeO-5 F-phenyl 841 (cPr)2CH 2-CH3-4-MeO-5-Cl-phenyl 842 phenyl (cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 843 2-furanyl (cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 844 3-furan(cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 845 2-thienyl(cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 846 3-thienyl(cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 847 2-isoxazolyl (cPr) CH 2-CH3-4-MeO-5-Cl-phenyl 848 2- (5-CH3-furanyl) (cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 849 2-(4-CH3-isoxazolyl) (cPr)CH 2-CH3-4-MeO-5-Cl-phenyl 850 cPr-CH(CH3) 2-CH3-4-MeO-5-Cl-phenyl 851 l-cPr-CH(CH2CH3) 2-CH3-4-MeO-5-Cl-phenyl 852 1-cPr-CH (CH2CH2CH3 ) 2-CH3-4-MeO-5-Cl-phenyl 853 l-cPr-CH(CH20CH3) 2-CH3-4-MeO-5-Cl-phenyl 854 1-cPr-CH (CH2CH2OCH3 ) 2-CH3-4-MeO-5-Cl-phenyl 855 (cBu)2CH 2-CH3-4-MeO-5-Cl-phenyl 856 phenyl (cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 857 2-furanyl (cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 858 3-furan(cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 859 2-thienyl(cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 860 3-thienyl(cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 861 2-isoxazolyl (cBu) CH 2-CH3-4-MeO-5-Cl-phenyl 862 2- (5-CH3-furanyl) (cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 863 2-(4-CH3-isoxazolyl) (cBu)CH 2-CH3-4-MeO-5-Cl-phenyl 864 cBu-CH(CH3) 2-CH3-4-MeO-5-Cl-phenyl 865 l-cBu-CH(CH2CH3) 2-CH3-4-MeO-5-Cl-phenyl 866 1-cBu-CH (CH2CH2CH3 ) 2-CH3-4-MeO-5-Cl-phenyl 867 l-cBu-CH(CH20CH3) 2-CH3-4-MeO-5-Cl-phenyl 868 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-4-MeO-5-Cl-phenyl 869 (cPr)2CH 2 , 5-diCH3-4-MeO-phenyl 870 phenyl (cPr)CH 2 , 5-diCH3-4-MeO-phenyl 871 2- furanyl (cPr)CH 2 , 5-diCH3-4-MeO-phenyl 872 3-furan(cPr)CH 2 , 5-diCH3-4-MeO-phenyl 873 2-thienyl(cPr)CH 2 , 5-diCH3-4-MeO-phenyl 874 3-thienyl(cPr)CH 2 , 5-diCH3-4-MeO-phenyl 875 2-isoxazolyl (cPr) CH 2 , 5-diCH3-4-MeO-phenyl 876 2- (5-CH3-furanyl) (cPr)CH 2 , 5-diCH3-4-MeO-phenyl 877 2-(4-CH3-isoxazolyl) (cPr)CH 2 , 5-diCH3-4-MeO-phenyl 878 cPr-CH(CH3) 2 , 5-diCH3-4-MeO-phenyl 879 l-cPr-CH(CH2CH3) 2 , 5-diCH3-4-Me0-phenyl 880 l-cPr-CH(CH2CH2CH3) 2 , 5-diCH3-4-MeO-phenyl 881 l-cPr-CH(CH20CH3) 2 , 5-diCH3-4-MeO-phenyl 882 l-cPr-CH(CH2CH20CH3) 2 , 5-diCH3-4-MeO-phenyl 883 (cBu)2CH 2 , 5-diCH3-4-MeO-phenyl 884 phenyl (cBu)CH 2 , 5-diCH3-4-MeO-phenyl 885 2-furanyl ( CBu) CH 2 , 5-diCH3-4-MeO-phenyl 886 3-furan(cBu)CH 2 , 5-diCH3-4-MeO-phenyl 887 2-thienyl(cBu)CH 2 , 5-diCH3-4-MeO-phenyl 888 3-thienyl(cBu)CH 2 , 5-diCH3-4-MeO-phenyl 889 2-isoxazolyl (cBu)CH 2 , 5-diCH3-4-MeO-phenyl 890 2- (5-CH3-1uranyl ) (cBu)CH 2 , 5-diCH3-4-MeO-phenyl 891 2-(4-CH3-isoxazolyl) (cBu)CH 2 , 5-diCH3-4-MeO-phenyl 892 cBu-CH(CH3) 2 , 5-diCH3-4-MeO-phenyl 893 l-cBu-CH(CH2CH3) 2 , 5-diCH3-4-MeO-phenyl 894 l-cBu-CH(CH2CH2CH3) 2 , 5-diCH3-4-MeO-phenyl 895 l-cBu-CH(CH20CH3) 2 , 5-diCH3-4-MeO-phenyl 896 l-cBu-CH(CH2CH20CH3) 2 , 5-diCH3-4-MeO-phenyl 897 (cPr)2CH 2-CH3-4-MeO-5-F-phenyl 898 phenyl (cPr)CH 2-CH3-4-MeO-5-F-phenyl 899 2-furanyl (cPr)CH 2-CH3-4-MeO-5-F-phenyl 900 3-furan(cPr)CH 2-CH3-4-MeO-5-F-phenyl 901 2-thienyl (cPr) CH 2-CH3-4-MeO-5-F-phenyl 902 3-thienyl(cPr)CH 2-CH3-4-MeO-5-F-phenyl 903 2-isoxazolyl (cPr)CH 2-CH3-4-MeO-5-F-phenyl 904 2 - ( 5-CH3-furanyl ) (cPr) CH 2-CH3-4-MeO-5-F-phenyl 905 2-(4-CH3-isoxazolyl) (cPr)CH 2-CH3-4-MeO-5-F-phenyl 906 cPr-CH(CH3) 2-CH3-4-MeO-5-F-phenyl 907 l-cPr-CH(CH2CH3) 2-CH3-4-MeO-5-F-phenyl 908 l-cPr-CH(CH2CH2CH3) 2-CH3-4-MeO-5-F-phenyl 909 l-cPr-CH(CH20CH3) 2-CH3-4-MeO-5-F-phenyl 910 l-cPr-CH(CH2CH20CH3) 2-CH3-4-MeO-5-F-phenyl 911 (cBu)2CH 2-CH3-4-MeO-5-F-phenyl 912 phenyl (cBu)CH 2-CH3-4-MeO-5-F-phenyl 913 2-furanyl (cBu)CH 2-CH3-4-MeO-5-F-phenyl 914 3-furan(cBu)CH 2-CH3-4-MeO-5-F-phenyl 915 2-thienyl (cBu)CH 2-CH3-4-MeO-5-F-phenyl 916 3-thienyl(cBu)CH 2-CH3-4-MeO-5-F-phenyl 917 2-isoxazolyl (cBu)CH 2-CH3-4-MeO-5-F-phenyl 918 2- (5-CH3-furanyl) (cBu)CH 2-CH3-4-MeO-5-F-phenyl 919 2-(4-CH3-isoxazolyl) (cBu)CH 2-CH3-4-MeO-5-F-phenyl 920 cBu-CH(CH3) 2-CH3-4-MeO-5-F-phenyl 921 l-cBu-CH(CH2CH3) 2-CH3-4-MeO-5-F-phenyl 922 1-cBu-CH (CH2CH2CH3 ) 2-CH " 3-4-MeO-5-F-phenyl 923 l-cBu-CH(CH20CH3) 2-CH3-4-MeO-5-F-phenyl 924 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-4-MeO-5-F-phenyl 925 (cPr)2CH 2,4, 6-triCH3-phenyl 926 phenyl (cPr)CH 2,4, 6-triCH3-phenyl 927 2-furanyl(cPr)CH 2,4, 6-triCH3-phenyl 928 3-furan(cPr)CH 2,4, 6-triCH3-phenyl 929 2-thienyl(cPr)CH 2,4,6-triCH3-phenyl 930 3-thienyl(cPr)CH 2,4,6-triCH3-phenyl 931 2-isoxazolyl (cPr) CH 2,4, 6-triCH3-phenyl 932 2- (5-CH3-furanyl) (cPr)CH 2,4, 6-triCH3-phenyl 933 2-(4-CH3-isoxazolyl) (cPr)CH 2,4, 6-triCH3-phenyl 934 cPr-CH(CH3) 2,4, 6-triCH3-phenyl 935 l-cPr-CH(CH2CH3) 2,4, 6-triCH3-phenyl 936 l-cPr-CH(CH2CH2CH3) 2,4, 6-triCH3-phenyl 937 l-cPr-CH(CH20CH3) 2,4, 6-triCH3-phenyl 938 1-cPr-CH (CH2CH2OCH3 ) 2,4, 6-triCH3-phenyl 939 (cBu)2CH 2,4, 6-triCH3-phenyl 940 phenyl (cBu)CH 2,4, 6-triCH3-phenyl 941 2-furanyl(cBu)CH 2,4, 6-triCH3-phenyl 942 3-furan(cBu)CH 2,4, 6-triCH3-phenyl 943 2-thienyl(cBu)CH 2,4, 6-triCH3-phenyl 944 3-thienyl (cBu)CH 2,4, 6-triCH3-phenyl 945 2-isoxazolyl (cBu)CH 2,4, 6-triCH3-phenyl 946 2- (5-CH3-furanyl) (cBu)CH 2,4, 6-triCH3-phenyl 947 2-(4-CH3-isoxazolyl) (cBu)CH 2,4,6-triCH3-phenyl 948 cBu-CH(CH3) 2,4,6-triCH3-phenyl 949 l-cBu-CH(CH2CH3) 2,4,6-triCH3-phenyl 950 1-cBu-CH (CH2CH2CH3 ) 2,4, 6-triCH3-phenyl 951 l-cBu-CH(CH20CH3) 2 , 4, 6-triCH3-phenyl 952 1-cBu-CH (CH2CH2OCH3 ) 2,4, 6-triCH3-phenyl 953 (cPr)2CH 3-pyridyl 954 phenyl (cPr)CH 3-pyridyl 955 2- furanyl (cPr)CH 3-pyridyl 956 3-furan(cPr)CH 3-pyridyl 957 2-thienyl(cPr)CH 3-pyridyl 958 3-thienyl (cPr) CH 3-pyridyl 959 2-isoxazolyl (cPr) CH 3-pyridyl 960 2- (5-CH3-furanyl) (cPr)CH 3-pyridyl 961 2-(4-CH3-isoxazolyl) (cPr)CH 3-pyridyl 962 cPr-CH(CH3) 3-pyridyl 963 l-cPr-CH(CH2CH3) 3-pyridyl 964 1-cPr-CH (CH2CH2CH3 ) 3-pyridyl 965 l-CPr-CH(CH20CH3) 3-pyridyl 966 1-cPr-CH (CH2CH2OCH3 ) 3-pyridyl 967 (cBu)2CH 3-pyridyl 968 phenyl (cBu)CH 3-pyridyl 969 2-furanyl (cBu)CH 3-pyridyl 970 3-furan(cBu)CH 3-pyridyl 971 2-thienyl(cBu)CH 3-pyridyl 972 3-thienyl(cBu)CH 3-pyridyl 973 2-isoxazolyl (cBu) CH 3-pyridyl 974 2- (5-CH3-furanyl) (cBu)CH 3-pyridyl 975 2-(4-CH3-isoxazolyl) (cBu)CH 3-pyridyl 976 cBu-CH(CH3) 3-pyridyl 977 l-cBu-CH(CH2CH3) 3-pyridyl 978 l-cBu-CH(CH2CH2CH3) 3-pyridyl 979 l-cBu-CH(CH20CH3) 3-pyridyl 980 1-cBu-CH (CH2CH2OCH3 ) 3-pyridyl 981 (cPr)2CH 2 , 6-diMeO-pyrid- -3- -yl 982 phenyl (cPr)CH 2 , 6-diMeO-pyrid- -3- -yl 983 2-furanyl (cPr)CH 2 , 6-diMeO-pyrid- -3- -yl 984 3-furan(cPr)CH 2 , 6-diMeO-pyrid- -3- -yi 985 2-thienyl (cPr)CH 2, 6-diMeO-pyrid- -3- -yl 986 3-thienyl(cPr)CH 2 , 6-diMeO-pyrid- -3- -yl 987 2-isoxazolyl (cPr) CH 2 , 6-diMeO-pyrid- -3- -yl 988 2- (5-CH3-furanyl) (cPr)CH 2, 6-diMeO-pyrid- -3- -yl 989 2-(4-CH3-isoxazolyl) (cPr)CH 2, 6-diMeO-pyrid- -3- -γi 990 cPr-CH(CH3) 2 , 6-diMeO-pyrid- -3- -yl 991 l-cPr-CH(CH2CH3) 2, 6-diMeO-pyrid-3-yl 992 1-cPr-CH (CH2CH2CH3 ) 2, 6-diMeO-pyrid-3-yl 993 l-cPr-CH(CH20CH3) 2, 6-diMeO-pyrid-3-yl 994 1-cPr-CH (CH2CH2OCH3 ) 2, 6-diMeO-pyrid-3-yl 995 (cBu)2CH 2, 6 - diMeO-pyr id- 3 -yl 996 phenyl (cBu)CH 2 6-diMeO-pyrid-3-yl 997 2- furanyl (cBu)CH 2 6-diMeO-pyrid-3-yl 998 3-furan(cBu)CH 2, 6-diMeO-pyrid-3-yl 999 2-thienyl(cBu)CH 2, 6-diMeO-pyrid-3-yl 1000 3-thienyl(cBu)CH 2, 6-diMeO-pyrid-3-yl 1001 2 -isoxazolyl (cBu) CH 2, 6-diMeO-pyrid-3-yl 1002 2- (5-CH3- furanyl) (cBu)CH 2 6-diMeO-pyrid-3-yl 1003 2-(4-CH3-isoxazolyl) (cBu)CH 2 6-diMeO-pyrid-3-yl 1004 cBu-CH(CH3) 2, 6-diMeO-pyrid-3-yl 1005 l-cBu-CH(CH2CH3) 2 6-diMeO-pyrid-3-yl 1006 1-cBu-CH (CH2CH2CH3 ) 2 6-diMeO-pyrid-3-yl 1007 l-cBu-CH(CH20CH3) 2 6-diMeO-pyrid-3-yl 1008 1-cBu-CH (CH2CH2OCH3 ) 2 6-diMeO-pyrid-3-yl 1009 (cPr)2CH 2 6-diCH3-pyrid-3-yl 1010 phenyl (cPr)CH 2 6-diCH3-pyrid-3-yl 1011 2-furanyl(cPr)CH 2 6-diCH3-pyrid-3-yl 1012 3-furan(cPr)CH 2 6-diCH3-pyrid-3-yl 1013 2-thienyl(cPr)CH 2 6 -diCH3 -pyrid- 3 -yl 1014 3-thienyl(cPr)CH 2 6-diCH3-pyrid-3-yl 1015 2-isoxazolyl (cPr) CH 2 6 -diCH3 -pyrid- 3 -yl 1016 2- (5-CH3-f uranyl) (cPr)CH 2 6-diCH3-pyrid-3-yl 1017 2- (4-CH3- isoxazolyl) (cPr)CH 2 6-diCH3-pyrid-3-yl 1018 cPr-CH(CH3) 2 6-diCH3-pyrid-3-yl 1019 l-cPr-CH(CH2CH3) 2 6-diCH3-pyrid-3-yl 1020 1-cPr-CH (CH2CH2CH3 ) 2 6-diCH3-pyrid-3-yl 1021 l-cPr-CH(CH20CH3) 2 6-diCH3-pyrid-3-yl 1022 1-cPr-CH (CH2CH2OCH3 ) 2 6-diCH3-pyrid-3-yl 1023 (cBu)2CH 2 6-diCH3-pyrid-3-yl 1024 phenyl (cBu)CH 2 6-diCH3-pyrid-3-yl 1025 2- furanyl (cBu)CH 2 6-diCH3-pyrid-3-yl 1026 3-furan(cBu)CH 2 6 -diCH3 -pyrid- 3 -yl 1027 2- thienyl ( cBu) CH 2 6-diCH3-pyrid-3-yl 1028 3-thienyl(cBu)CH 2 6-diCH3-pyrid-3-yl 1029 2-isoxazolyl (cBu) CH 2 , 6-diCH3-pyrid-3-yl 1030 2- (5-CH3- furanyl) (cBu)CH 2 , 6-diCH3-pyrid-3-yl 1031 2-(4-CH3-isoxazolyl) (cBu)CH 2 , 6-diCH3-pyrid-3-yl 1032 cBu-CH(CH3) 2 , 6-diCH3-pyrid-3-yl 1033 l-cBu-CH(CH2CH3) 2 , 6-diCH3-pyrid-3-yl 1034 1-cBu-CH (CH2CH2CH3 ) 2 , 6-diCH3-pyrid-3-yl 1035 l-cBu-CH(CH20CH3) 2 , 6-diCH3-pyrid-3-yl 1036 1-cBu-CH (CH2CH2OCH3 ) 2 , 6-diCH3-pyrid-3-yl 1037 (cPr)2CH 2-CH3-6-Me0-pyrid-3-yl 1038 phenyl (cPr)CH 2-CH3-6-Me0-pyrid-3-yl 1039 2- f uranyl (cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1040 3-furan(cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1041 2-thienyl(cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1042 3-thienyl(cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1043 2-isoxazolyl (cPr) CH 2-CH3-6-MeO-pyrid-3-yl 1044 2- (5-CH3- furanyl) (cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1045 2-(4-CH3-isoxazolyl) (cPr)CH 2-CH3-6-MeO-pyrid-3-yl 1046 cPr-CH(CH3) 2-CH3-6-MeO-pyrid-3-yl 1047 l-cPr-CH(CH2CH3) 2-CH3-6-MeO-pyrid-3-yl 1048 l-cPr-CH(CH2CH2CH3) 2-CH3-6-MeO-pyrid-3-yl 1049 l-cPr-CH(CH20CH3) 2-CH3-6-MeO-pyrid-3-yl 1050 1-cPr-CH (CH2CH2OCH3 ) 2-CH3-6-MeO-pyrid-3-yl 1051 (cBu)2CH 2-CH3-6-MeO-pyrid-3-yl 1052 phenyl (cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1053 2- furanyl (cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1054 3-furan(cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1055 2-thienyl(cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1056 3-thienyl(cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1057 2 - isoxazolyl ( cBu) CH 2-CH3-6-MeO-pyrid-3-yl 1058 2- (5-CH3- furanyl) (cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1059 2- (4-CH3-isoxazolyl) (cBu)CH 2-CH3-6-MeO-pyrid-3-yl 1060 cBu-CH(CH3) 2-CH3-6-MeO-pyrid-3-yl 1061 l-cBu-CH(CH2CH3) 2-CH3-6-MeO-pyrid-3-yl 1062 1-cBu-CH (CH2CH2CH3 ) 2-CH3-6-MeO-pyrid-3-yl 1063 l-cBu-CH(CH20CH3) 2-CH3-6-MeO-pyrid-3-yl 1064 1-cBu-CH (CH2CH2OCH3 ) 2-CH3-6-MeO-pyrid-3-yl 1065 (cPr)2CH 4-CH3-6-MeO-pyrid-3-yl 1066 phenyl (cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1067 2-furanyl ( cPr) CH 4-CH3-6-MeO-pyrid-3-yl 1068 3-furan(cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1069 2-thienyl(cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1070 3-thienyl(cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1071 2-isoxazolyl (cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1072 2- (5-CH3-1uranyl ) (cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1073 2-(4-CH3-isoxazolyl) (cPr)CH 4-CH3-6-MeO-pyrid-3-yl 1074 cPr-CH(CH3) 4-CH3-6-MeO-pyrid-3-yl 1075 l-cPr-CH(CH2CH3) 4-CH3-6-MeO-pyrid-3-yl 1076 l-cPr-CH(CH2CH2CH3) 4-CH3-6-MeO-pyrid-3-yl 1077 l-cPr-CH(CH20CH3) 4-CH3-6-MeO-pyrid-3-yl 1078 l-cPr-CH(CH2CH20CH3) 4-CH3-6-MeO-pyrid-3-yl 1079 (cBu)2CH 4-CH3-6-MeO-pyrid-3-yl 1080 phenyl (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1081 2-furanyl (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1082 3-furan(cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1083 2-thienyl(cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1084 3-thienyl (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1085 2-isoxazolyl (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1086 2- (5-CH3-furanyl) (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1087 2-(4-CH3-isoxazolyl) (cBu)CH 4-CH3-6-MeO-pyrid-3-yl 1088 cBu-CH(CH3) 4-CH3-6-MeO-pyrid-3-yl 1089 l-cBu-CH(CH2CH3) 4-CH3-6-MeO-pyrid-3-yl 1090 l-cBu-CH(CH2CH2CH3) 4-CH3-6-MeO-pyrid-3-yl 1091 l-cBu-CH(CH20CH3) 4-CH3-6-MeO-pyrid-3-yl 1092 l-cBu-CH(CH2CH20CH3) 4-CH3-6-MeO-pyrid-3-yl 1093 (cPr)2CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1094 phenyl (cPr)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1095 2-furanyl(cPr)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1096 3-furan(cPr)CH 4-CH3-6- (CH3) 2N-pyrid-3-yl 1097 2-thienyl(cPr)CH 4-CH3-6- (CH3) 2N-pyrid-3-yl 1098 3-thienyl(cPr)CH 4-CH3-6- (CH3) 2N-pyrid-3-yl 1099 2-isoxazolyl (cPr)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1100 2- (5-CH3-1uranyl ) (cPr)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1101 2-(4-CH3-isoxazolyl) (cPr)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1102 cPr-CH(CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1103 l-cPr-CH(CH2CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1104 l-cPr-CH(CH2CH2CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1105 l-cPr-CH(CH20CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1106 1-cPr-CH (CH2CH2OCH3 ) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1107 (cBu)2CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1108 phenyl (cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1109 2- furanyl (cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1110 3-furan(cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1111 2-thienyl(cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1112 3-thienyl(cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1113 2-isoxazolyl (cBu) CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1114 2- (5-CH3- furanyl) (cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1115 2-(4-CH3-isoxazolyl) (cBu)CH 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1116 cBu-CH(CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1117 l-cBu-CH(CH2CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1118 1-cBu-CH (CH2CH2CH3 ) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1119 l-cBu-CH(CH20CH3) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1120 1-cBu-CH (CH2CH2OCH3 ) 4-CH3-6- (CH3 ) 2N-pyrid-3-yl 1121 3-pentyl 2,4,6-(CH3)3 phenyl 1122 3-pentyl 2,4-Cl2- 5 -F-phenyl 1123 3-pentyl 2,4- (MEO) 2 -phenyl 1124 3-pentyl 2,4-Cl 2 - phenyl 1 3-pentyl 2,4-Cl 2 - phenyl Table 1 shows compounds which may readily be prepared according to the procedures described herein in the synthetic schemes and text. The preferred compounds have a core of e 4 with the exception of Examples 95 and 1124, which have cores of c 4 and f 4 respectively. Example 1 has a melting point of 136-138°C. Utility Compounds of this invention are expected to have utility in the treatment of inbalances associated with abnormal levels of CRF in patients suffering from depression, affective disorders, and/or anxiety. CRF-Rl Receptor Binding Assay for the Evaluation of Biological Activity The following is a description of the isolation of cell membranes containing cloned human CRF-Rl receptors for use in the standard binding assay as well as a description of the assay itself. Messenger RNA was isolated from human hippocampus . The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using Xhol + Xbal and cloned into the Xhol + Xbal sites of vector pm3ar ( which contains a CMV promoter, the SV40 ' t' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker) . The resulting expression vector, called phchCRFR was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 μM hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10^ of the suspended cells were then centrifuged to form a pellet and frozen. For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFRl receptors is homogenized in 10 ml of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM MgCl2, 2 mM EGTA, 1 μg/1 aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin) . The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 ml of tissue buffer. After another centrifugation at 40,000 x g for 12 min, the pellet is resuspended to a protein concentration of 360 μg/ml to be used in the assay. Binding assays are performed in 96 well plates; each well having a 300 μl capacity. To each well is added 50 μl of test drug dilutions (final concentration of drugs range from 10-10 - 10- 5 M) , 100 μl of 125 I-ovine-CRF ( 12 5i-o-CRF) (final concentration 150 pM) and 150 μl of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter. Curves of the inhibition of 2 5ι-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND [P.J. Munson and D. Rodbard, Anal . Biochem. 107:220 (1980)], which provides Ki values for inhibition which are then used to assess biological activity. A compound is considered to be active if it has a Ki value of less than about 10000 nM for the inhibition of CRF. Alternatively, tissues and cells which naturally express CRF receptors can be employed in binding assays analogous to those described above. Inhibition of CRF-S imulated Adenvla e Cvclase Activity Inhibition of CRF-stimulated adenylate cyclase activity can be performed as described by G. Battaglia et al . Synapse 1:572 (1987). Briefly, assays are carried out at 37° C for 10 min in 200 ml of buffer containing 100 mM Tris-HCl (pH 7.4 at 37° C), 10 mM MgCl2, 0.4 M EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX) , 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5'- triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10-9 to 10 ~ 6m) an( j o .8 mg original wet weight tissue (approximately 40-60 mg protein) . Reactions are initiated by the addition of 1 mM ATP/[ 32 P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 ml of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 μl of [ 3 H]cAMP (approximately 40,000 dp ) is added to each tube prior to separation. The separation of [3 2 P]cAMP from [3 p]ATP is performed by sequential elution over Dowex and alumina columns. Tri vi vo Biological Assay The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C.W. Berridge and A.J. Dunn Brain Research Reviews 15:71 (1990). Compounds may be tested in any species of rodent or small mammal. Dosage and Formulation Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect. Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition. The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations. Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance. In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol . Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Cansul s A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate. Soft Gelatin Cansul s A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption. The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease. Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings . It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims: WHAT IS CLAIMED AS NEW AND DESIRED TO BE SECURED BY LETTER PATENT OF UNITED STATES IS: 1. A compound of formula (I) (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 - 10 alkenyl, C 2 - 10 alkynyl, C 3 _8 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, -SO 2 -Cι_ι 0 alkyl, -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , -NR 15 COR 13a , -N(COR 13 ) 2 , -NR 1 CONR 13a R 15a , -NR 15a C0 2 R 14b , ~CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 -. 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0)n-, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NSO 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group _13a . τ -,14b _,^, τ .14b , „~. τ -,14b R , CO 2 R , COR and SO2R ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cχ- 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -OR 13 , -NR 13a R 16a , C 1 -4 alkoxy-Cι_ alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cχ- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S OmR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17 R 19 a and each heteroaryl being substituted on any nitrogen 15a atom with 0-1 substituents selected from the group R C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cχ- 6 alkyl, C 3 -- 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13 , -OC(0)R 1 b , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13 R 16 , -NR 15a C0 2 R 14b , -NR 1 a R 16a , and -CONR 13 R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl, - (CH 2 ) 1 - 4 -heteroaryl, or - (CH 2 ) 1 - 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C1- 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, Cι_ 4 alkylthio, Cι_ 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C - 6 alkylamino and (C 1 - 4 alkyl) 2 amino; R 9 and R 10 are independently selected at each occurrence from the group H, Cχ- 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 -. 4 alkyl, Cχ_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, aryl, aryl(Cι- 4 alkyl)-, heteroaryl and heteroaryl (Ci- 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, C 3 _6 cycloalkyl-Cι-6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group Cι_ 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C3-6 cycloalkyl, C3.-6 cycloalkyl-Cι-6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C3-7 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, nitro, Cχ- 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 .- 6 cycloalkyl- Ci-e alkyl; R 17 is selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι- 2 alkyl, C 1 -4 haloalkyl, R 1 S (O) n -Cι- 4 alkyl, and R 17b R 19b N-C 2 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C3-10 cycloalkyl, C 3 -6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and Cι_4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; a nlt-ernativel 1y, i ■n an -NrnR 17 krR, 19b moi ■e 4t-y, π R1 b and , R19b t .a ,ken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cχ- 6 alkyl, C 3 _ι 0 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl and C 1 - 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl , naphthyl , indanyl and indenyl , each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C- 1 -4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2, 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 _e cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , Cθ 2 R 14a , COR 1 a and S0 2 R 14a ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted Cι_ 6 linear or branched alkyl or C 3 _ 6 cycloalkyl . A compound according to Claim 1, wherein the compound is of formula la: (la) A compound according to Claim 1, wherein the compound is of formula lb: (lb) . A compound according to Claim 1, wherein the compound is of formula lc: (lc) A compound according to Claim 1 , wherein the compound is of formula Id : ( Id) . 6. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post- traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl cr heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0 , 1 or 2 ; R 1 is selected from the group Ci-io alkyl, C 2 - 10 alkenyl, C 2 - 10 alkynyl, C 3 - 8 cycloalkyl, C3- 6 cycloalkyl-Cι_ 6 alkyl, C1- 4 alkoxy-Cι- 4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(C0R 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NSO 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group π R13a, C„O„ 2τ R-,14b, C_,O„ π R14b a„„nd-, S„O„2 r R > 14b ; 1 R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Ci- 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -OR 13a , -NR 13 R 16 , C 1 - 4 alkoxy-Cι_ 4 alkyl, and 9 C 3 _ 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 -. 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Ci_ 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19 , and -C0NR 17a R 19a ; R l is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2,3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17 R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen 15a atom with 0-1 substituents selected from the group R , C0 2 R 14b _, Λrι 14b , „ τ -,14b COR and S0 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -C0R 13a , -0C(0)R 14b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15 C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 1 b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, Cι_ alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, Cι_ 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (Cι_ 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group Cι_ 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, Cι_ 4 alkylthio, C _ 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C - 6 alkylamino and (C 1 - 4 alkyl) 2 mino; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 _ 6 cycloalkyl-Cι_ 4 alkyl and C 3 -8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C U 11 -- 44 aalιkκooxxyy--C^ιι__ 44 aalkκyylι,, C 33 -- 66 ccyycclιooaalkκyylι,, CL. 33 -- 66 ccyycloalkyl- CC1 1 -- 66 aallkkyyll,, aarryyll,, aarryyKKCCιι-- 44 aallkkyyll))--,, hheetteerrooaarryyll and hheetteerrooaarryyll ((CCIi--Λ 4 aallkkvyll))--;; R 13a and R 16 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3_6 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R l4a j_ s selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Cι_ 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 -4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino,- R 14b is selected from the group C 1 - 4 alkyl, Cχ_ 4 haloalkyl, C _ 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 -. 6 cycloalkyl- C 1 - 6 alkyl; R 15 is independently selected at each occurrence from the group H, Cι_ 4 alkyl, C 3 _ 7 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 _ 6 cycloalkyl- C 1 - 6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι_6 alkyl, C1-2 alkoxy-Cι- 2 alkyl, C 1 - 4 haloalkyl, R 1 S (O) n -Cι_ alkyl, and R 17b R 19b N-C 2 - 4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 _ 6 cycloalkyl-Cι- 6 alkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and Cι_4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; alternatively, in an NR 17 R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι-6 alkyl, C 3 -1 0 cycloalkyl, C3- 6 cycloalkyl-Cι- 6 alkyl and C1- 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl , indanyl and indenyl , each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C1- 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(C0R 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 1 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2,3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cι_4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , Cθ 2 R 14a , COR 14a and S0 2 R 14a . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 -ιo alkenyl, C 2 -ιo alkynyl, C 3 _ 8 cycloalkyl, C 3 - 6 cycloalkyl-C 1 _ 6 alkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R l , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16 , -NR 15a C0 2 R 14b , -CONR 13a R 15 , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 _s cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and 14b -NSO 2 R -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group π 13a __ π 14b _,_ r ,14b , „ π 14b R , CO 2 R , COR and SO 2 R ; 1 R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -OR 13a , -NR 13 R 16a , C 1 - 4 alkoxy-Cι_ alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19a , -NR 15 C0 2 R 18 , -NR 17 R 19a , and -CONR 17 R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2, 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , τ -,14 _,^._,14b -, „^ τ ^!4 CO2R , COR and SO 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13a , -OC(0)R 1 b , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13 R 15a , -NR 15 C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein an} sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 -. 4 alkyl, C 3 _s cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C- 1 -4 alkyl, C 3 _ 8 cycloalkyl, C 1 - 4 alkoxy, Cι_ 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) 2 mino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl ) 2 mino; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1-4 alkoxy-Cι- 4 alkyl, C3- 6 cycloalkyl, C 3 - 6 cycloalkyl- Cι- 6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 _ 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group Cι_ 4 alkyl, C 1 - 4 haloalkyl, C1-4 alkoxy-Cι_ 4 alkyl, C 3 _ 6 cycloalkyl, C3_ 6 cycloalkyl-Cι-6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 1 a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Cι_6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 1 b is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 -7 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl , phenyl and benzyl , each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl- Cι_6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι_ 6 alkyl, C1-2 alkoxy-Cι_ 2 alkyl, C1-4 haloalkyl, R 14 S (0) n -Cι_4 alkyl, and R 17 R 19b N-C 2 - alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl; alternatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; anl,t_erna *t.i •ve 1ly, m• an -Nκ-mRl7b_R19b moi.et.y, τR-,17b and-, _R19b t.a,ken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Ci-e alkyl, C 3 - 10 cycloalkyl, C 3 _ 6 cycloalkyl-Cι_ 6 alkyl and C1- 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 -6 cycloalkyl, methylenedioxy, Cι_ 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, Cι_ 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C-ι- 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -C0R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituαeenntts selected from the group R , CO 2 R a , COR ,14a and S0 2 R

Inventors: FRIETZE WILLIAM ERIC, GILLIGAN PAUL JOSEPH, OLSON RICHARD ERIC, FRIETZE, WILLIAM, ERIC, GILLIGAN, PAUL, JOSEPH, OLSON, RICHARD, ERIC
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1999
Main classification: C07D487
IPC codes: C07D471, C07D487